[go: up one dir, main page]

WO1994002173A1 - Multiple particulate antigen delivery system - Google Patents

Multiple particulate antigen delivery system Download PDF

Info

Publication number
WO1994002173A1
WO1994002173A1 PCT/US1993/006634 US9306634W WO9402173A1 WO 1994002173 A1 WO1994002173 A1 WO 1994002173A1 US 9306634 W US9306634 W US 9306634W WO 9402173 A1 WO9402173 A1 WO 9402173A1
Authority
WO
WIPO (PCT)
Prior art keywords
proteinε
proteins
btv
antigen
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/006634
Other languages
French (fr)
Inventor
Polly Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oxford
Original Assignee
University of Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929215101A external-priority patent/GB9215101D0/en
Application filed by University of Oxford filed Critical University of Oxford
Priority to AU47732/93A priority Critical patent/AU4773293A/en
Publication of WO1994002173A1 publication Critical patent/WO1994002173A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates to antigens in particulate form, especially antigens in the form of virus-like particles or virus core-like particles.
  • the invention particularly relates to chimeric antigens wherein foreign epitopes are presented on or within virus-like particles or virus core-like particles.
  • Viruses generally are composed of a plurality of different proteins assembled together in a regular arrangement together with DNA or RNA.
  • the proteins are often arranged in a layered or concentric manner with certain proteins cooperating to form the outer coat or capsid and others forming the so-called core or inner capsid.
  • virus proteins are capable of assembling in the absence of nucleic acid to form so-called virus-like particles or VLPs.
  • the proteins which normally cooperate together with nucleic acid to form the virus core can assemble in the absence of nucleic acid to form so-called core-like particles (CLPs).
  • CLPs core-like particles
  • virus-like particles and core-like particles will be used in the above sense to designate assemblages of virus proteins (or modified or chimeric virus proteins) in the absence of virus genomic nucleic acid.
  • immunogenic epitopes in entities which are in particulate form is highly desirable as such forms can be especially useful in for example the development of vaccines for oral or other mucosal routes of administration.
  • relatively few useful immunogenic epitopes can readily be produced in particulate form wherein the epitopes remain immunogenic.
  • the development of particulate vector systems for the presentation of immunogenic epitopes provides a powerful approach for the delivery of antigens.
  • Various types of particles have been used to present foreign epitopes, including particles formed from the hepatitis B virus (HBV) surface or core antigens, polioviru ⁇ es and yeast Ty-particle ⁇ (1-5).
  • VLPs and CLPs are examples of particulate antigens that possess immunogenic epitopes. These may often be located at or adjacent to the particle surface, although epitopes may also be located internally. Further, VLPs and CLPs are sufficiently stable and resistant to degradation to enable them to have potential use as vaccines when administered by the oral, respiratory or other mucosal routes, the latter property no doubt being associated with the fact that many viruses in native form are infectious orally. Examples of such viruses are members of the family Reoviridae.
  • the ⁇ ynthesi ⁇ of CLPs can be obtained by co-expression of VP3 and VP7 species representing different serotypes of BTV or other orbiviruses such as epizootic hae orrhagic disease virus (EHDV) VP3 and BTV VP7. Further the synthe ⁇ i ⁇ of VLPs can be obtained with genes representing different BTV ⁇ erotype ⁇ .
  • EHDV epizootic hae orrhagic disease virus
  • the present invention provides VLP ⁇ and CLPs which are immunogenic and especially such VLPs and CLPs which are useful in vaccine formulation. More particularly, the pre ⁇ ent invention provides genetically engineered, multi-component, virus-like particles (VLPs) and virus core-like particles (CLP ⁇ ) a ⁇ vaccine delivery systems for multiple immunogens representing viruses, bacteria and bacterial toxins that are responsible for human disea ⁇ e ⁇ (e.g. Hepatiti ⁇ B, HIV, Re ⁇ piratory Syncytial Viru ⁇ , Clo ⁇ tridium difficile, Bovine Leukemia Virus, Helicobacter pylori, etc.),
  • VLPs virus-like particles
  • CLP ⁇ virus core-like particles
  • an antigen in particulate form compri ⁇ ing a plurality of proteins capable of as ⁇ embly in cooperation with one another into virus-like particles (VLPs) or viru ⁇ core-like particles (CLPs), wherein the particles include fir ⁇ t and second different proteins each of which comprise ⁇ amino acid sequences derived respectively from fir ⁇ t and ⁇ econd native protein ⁇ of a selected viru ⁇ ⁇ pecie ⁇ and wherein at lea ⁇ t one of the first and second proteins is chimeric and compri ⁇ es an amino acid sequence derived from a foreign protein other than ⁇ aid fir ⁇ t or ⁇ econd native protein.
  • VLPs virus-like particles
  • CLPs viru ⁇ core-like particles
  • the invention provide ⁇ a method of producing chimeric VLP ⁇ or CLP ⁇ comprising at lea ⁇ t one non-native protein, in which the VLPs or CLP ⁇ are as ⁇ e bled from a plurality of different proteins including native virus proteins and the non-native protein.
  • the non-native protein comprises an amino acid sequence derived from a foreign protein and an amino acid ⁇ equence derived from a native viru ⁇ protein.
  • the invention provides a vaccine composition compri ⁇ ing an effective amount of an antigen of the invention, in as ⁇ ociation with a therapeutically acceptable carrier or diluent.
  • the invention al ⁇ o provide ⁇ a method of inducing a protective immunogenic re ⁇ ponse in a host in need of treatment, wherein an immunologically effective amount of an antigen according to the invention is administered to the host.
  • the antigen according to one aspect may be administered to a mucosal surface of said ho ⁇ t.
  • the antigen is administered orally.
  • the present invention is based upon the surpri ⁇ ing discovery that the above technology can be adapted to allow the formation of CLP ⁇ and VLPs which can be used to present foreign epitopes.
  • This is ba ⁇ ed on the finding by the pre ⁇ ent inventor that the VP7 protein i ⁇ located on the outer surface of the CLPs with VP3 forming an inner icosahedral subcore.
  • Introduction of a 14 amino acid sequence representing an immunogenic region of rabie ⁇ G protein to the amino terminus of VP3 results in expression of chimeric protein and the formation of CLPs when co-expressed with VP7.
  • chimeric BTV VP7 protein containing at least 48 foreign amino acids can be incorporated into CLPs and VLPs. More specifically, it has been determined that when the rabies 14 amino acid residues or amino acid residues 1-48 of the hepatitis B virus preS_ region are incorporated into the amino terminus of VP7, not only are the chimeric proteins expressed in infected cells but also they can be incorporated into CLPs on co-expression with VP3.
  • Clostridium difficle is the causative agent of colitis in humans.
  • Toxin A ply ⁇ an important role in the pathogeni ⁇ i ⁇ of thi ⁇ di ⁇ ea ⁇ e.
  • An oligonucleotide duplex coding for Clo ⁇ tridium difficle decapeptide Toxin A wa ⁇ cloned on the amino terminus of the VP7 gene using a dual vector coding for VP3 and VP7 (VP3 gene i ⁇ expressed under the control of the pclyhedrin promoter while VP7 gene with Smal and Spel (compatible with Xbal) cloning site ⁇ i ⁇ placed under the control of polyhedrin promoter.
  • Bovine Leukemia Virus (BLV) epitopes placed upstream of the amino terminus of BTV VP7 and cosynthesi ⁇ ed with BTV VP3 using recombinant baculovirus did not produce CLPs.
  • chimeric CLPs containing the fusion protein were produced when both unmodified BTV VP7 and the fusion protein were cosynthe ⁇ i ⁇ ed with BTV VP3.
  • Genes coding for the Helicobacter pylori urease ⁇ ubunit ⁇ A and B were produced by PCR and cloned in the pAcUW3 vector. Recombinant baculoviruse ⁇ were produced using thi ⁇ plasmid. S. frugiperda cells infected with the recombinant baculovirus produced both urease subunits A and B.
  • Antigens according to the invention which are in the form of CLP ⁇ generally comprise two es ⁇ ential protein ⁇ and one or more further optional proteins, wherein the es ⁇ ential proteins are virus major inner capsid proteins and the optional proteins are ⁇ elected from minor inner cap ⁇ id protein ⁇ .
  • the CLP ⁇ compri ⁇ e zero, one, two or three further optional virus minor inner capsid protein ⁇ .
  • Antigen ⁇ according to the invention wr: 1 ch are in the form of VLP ⁇ generally compri ⁇ e three e ⁇ ential protein ⁇ and one or more further optional protein ⁇ , wherein two of the e ⁇ ential protein ⁇ are viru ⁇ major inner capsid proteins, one of said essential proteins i ⁇ a viru ⁇ major outer capsid protein, and the optional protein ⁇ are selected from minor inner cap ⁇ id proteins and major outer capsid proteins.
  • the VLP ⁇ compri ⁇ e zero, or one further optional virus major outer cap ⁇ id protein ⁇ and/or zero, one, two or three further optional virus minor inner capsid proteins.
  • Antigens in particulate form according to the invention can comprise a plurality of proteins capable of assembly in cooperation with one another into virus core-like particles (CLPs).
  • the antigens include first and ⁇ econd different major structural proteins each of which comprises amino acid sequences derived re ⁇ pectively from first and second native proteins of a ⁇ elected viru ⁇ ⁇ pecie ⁇ or related virus species in the presence or absence of any one or combination of three minor proteins each of which comprise ⁇ amino acid ⁇ equences derived from the three minor proteins of a selected virus species or related virus specie ⁇ .
  • At lea ⁇ t one of any of the aforementioned five protein ⁇ i ⁇ chimeric and comprises an amino acid sequence derived from a foreign protein other than said native proteins.
  • antigens in particulate form can comprise a plurality of proteins capable of as ⁇ embly in cooperation with one another into virus-like particles (VLPs).
  • the antigens are characterized by including first, second, third and optionally fourth different major structural proteins each of which comprise ⁇ amino acid sequences derived respectively from first, second, third and fourth native proteins of a selected virus species or related virus species in the presence or ab ⁇ ence of any one or combination of three minor protein ⁇ each of which compri ⁇ e ⁇ amino acid ⁇ equence ⁇ derived from the three minor protein ⁇ of the ⁇ elected virus specie ⁇ or a related viru ⁇ species.
  • At least one of any of the aforementioned eight proteins i ⁇ chimeric and comprises an amino acid sequence derived from a foreign protein other than the native proteins.
  • the antigen ⁇ in particulate form con ⁇ i ⁇ ting of a CLP can compri ⁇ e two essential proteins and one or more further optional proteins, wherein the essential proteins are virus major inner capsid proteins VP3 and VP7 and the optional proteins are ⁇ elected from the minor inner capsid proteins VPl, VP4 and VP6.
  • the essential proteins are virus major inner capsid proteins VP3 and VP7 and the optional proteins are ⁇ elected from the minor inner capsid proteins VPl, VP4 and VP6.
  • VLPs can comprise three e ⁇ ential protein ⁇ and one or more further optional proteins, wherein two of the es ⁇ ential protein ⁇ are viru ⁇ major inner capsid proteins VP3 and VP7, one of the es ⁇ ential protein ⁇ i ⁇ a viru ⁇ major outer cap ⁇ id protein ⁇ elected from VP2 and VP5 and the optional protein ⁇ are ⁇ elected from minor inner cap ⁇ id protein ⁇ VPl, VP4 and VP6 and major outer cap ⁇ id protein ⁇ VP2 and VP5.
  • the ⁇ e combinations of proteins may be depicted as follows:
  • the antigens of the invention may be produced with at lea ⁇ t one of the protein ⁇ in native form and the ⁇ ame protein or proteins additionally being in chimeric form, i.e. incorporating amino acid sequences of a foreign protein.
  • Chimeric antigens in particulate form may be produced according to the invention wherein the amino acid sequence derived from the foreign protein includes an epitope which is recognized by an antibody to the foreign protein.
  • the foreign protein is a protein of a disease-producing organism and the antigen in particulate form is capable of raising protective (e.g. neutralizing) antibodies or cellular immune response in an organism susceptible to the disea ⁇ e.
  • the antigen ⁇ of the invention find special utility in the formulation of vaccines.
  • Chimeric VLPs or CLPs may include one or more of the incorporated major structural proteins in chimeric form.
  • the CLPs may include (i) a first virus protein in native form, (ii) a second viru ⁇ protein in native form, and (iii) one of the first and second viru ⁇ protein ⁇ in chimeric form compri ⁇ ing an amino acid ⁇ equences derived from native virus protein and an amino acid sequence derived from a foreign protein.
  • the VLPs may include (i) a first virus protein in native form, (ii) a second virus protein in native form, (iii) a third virus protein in native form and (iv) one of the first and second virus protein ⁇ in chimeric form comprising an amino acid sequences derived from native virus protein and an amino acid sequence derived from a foreign protein.
  • Chimeric VLP ⁇ or CLP ⁇ compri ⁇ ing at least one non-native protein are produced according to the invention by a ⁇ embling the VLP ⁇ or CLPs from a plurality of different proteins including native viru ⁇ protein ⁇ and the non-native protein.
  • the non-native protein compri ⁇ e ⁇ an amino acid ⁇ equence derived from a foreign protein and an amino acid sequence derived from a native virus protein.
  • the amino acid sequence derived from a foreign protein may be located at the N-terminal end of the chimeric protein, although other arrangements are al ⁇ o envi ⁇ aged according to the invention, for example wherein the amino acid sequence derived from a foreign protein is in ⁇ erted within the sequence of the native protein, or is located at the C-terminal end. It ha ⁇ been found that locating the amino acid sequence derived from a foreign protein at the N-terminal end of the chimeric protein enable ⁇ the foreign epitope to be immunogenic in the eventual VLP ⁇ or CLP ⁇ .
  • the antigen particles may be a ⁇ embled from their con ⁇ tit ⁇ ent components in a variety of ways. Thu ⁇ , for example, the component ⁇ may be produced separately and then ⁇ imply combined by mixing solutions of the constituent proteins in a suitable medium. However, it is preferred that the native and chimeric proteins are expressed together so that assembly of the antigen particles can take place without the expressed polypeptide being degraded, modified or otherwise proces ⁇ ed to a form incompatible with their a ⁇ embly to form VLP ⁇ or CLP ⁇ . Mo ⁇ t preferably the con ⁇ tituent protein ⁇ are co-expres ⁇ ed.
  • any suitable expression system may be employed, especially satisfactory results have been obtained using an expres ⁇ ion ⁇ ystem which includes a baculovirus expre ⁇ ion vector. Thu ⁇ , preferably the con ⁇ tituent proteins are expressed in insect ⁇ or insect cell ⁇ .
  • Figure 1 shows a recombinant transfer vector containing an HBV preS ⁇ sequence upstream and colinear with BTV VP7;
  • Figures 2A-2C show SDS PAGE analysi ⁇ of proteins produced by AcBTV7-preS 2 ;
  • Figure 3A-B show SDS-PAGE and We ⁇ tern immunoblot analy ⁇ e ⁇ of CLP ⁇ compo ⁇ ed of VP3 and VP7 (lane 1) or VP3, VP7 and preS 2 VP7 (lane ⁇ 2 and 3);
  • Figures 4A-B show immunogold-electron micro ⁇ cope photograph ⁇ of purified CLPs
  • Figures 5A-C show SDS-PAGE and Western immunoblot analy ⁇ es relating to immunogenicity of chimeric CLPs
  • Figure 6 is a Western blot analy ⁇ i ⁇ carried out utilizing anti-BTV and anti-V3 (HIV-1) sera again ⁇ t native BTV/BTV VP7, chimeric BTV VP7/HIV-1 V3, CLPs derived from native BTV VP3/BTV VP7 and chimeric CLP ⁇ derived from BTV VP3/chimeric BTV VP7/HIV-1 V3;
  • Figure 7 shows ⁇ the junction between the Clostridium difficile toxin A and the amino terminus of the BTV-10 VP7;
  • Figure 8 ⁇ how ⁇ PAGE of CLP ⁇ and chimeric CLPs carrying the clo ⁇ tridium difficile Toxin A decapeptide;
  • Figure 9 how ⁇ a Western blot of CLPs and chimeric CLP ⁇ with anti-decapeptide anti ⁇ erum.
  • Figure 10 hows construction of BLV epitopes and BTV VP7 recombinant protein ⁇
  • Figure 11A and B shows Western blot for expression of recombinant baculoviruses.
  • Recombinant virus-infected Sf cell lysate were blotted on the membrane and reacted with (A) anti-VP7 rabbit serum and (B) anti-pp(142-161) rabbit serum.
  • Figure 12 shows SDS-PAGE (A) and Western blot analysis (B) of chimeric CLPs using anti-VP7 rabbit serum (a) and anti-pp (142-161) rabbit serum (b) .
  • Figure 13 shows DNA and amino acid sequences of VP7 after insertion of p8/p9 and p6/p7 oligonucleotide duplexes. Both in ⁇ ertion contain unique PpUMI site (underlined) in order to use it for subsequent cloning of foreign epitopes;
  • Figure 14 show ⁇ the B ⁇ XI maps of the initial VP7 gene and the genes with insertions
  • Figure 15 shows agarose gel electrophore ⁇ is of BamHI/BstXI digests of initial pUC4K-BTVI-VP7 and the clones with insertions. Fragments smaller than 350 b.p. run out of the gel;
  • Figure 16 how ⁇ mutation ⁇ of VP7 with creation of cloning ⁇ ite ⁇
  • Figure 17 shows restriction endonuciease analysis of mutated VP7 genes with created Bglll and Seal sites;
  • Figure 18 show ⁇ PAGE of the lysates of S. fru ⁇ iperda cells infected with recombinant baculoviru ⁇ expre ⁇ sing the Helicobacter pylori urease A and B subunit ⁇ ;
  • Figure 19 how ⁇ We ⁇ tern blot of the ly ⁇ ate ⁇ of S. frugiperda cell ⁇ infected with recombinant baculoviru ⁇ expre ⁇ ing the Helicobacter pylori urease A and B subunit ⁇ ;
  • Figure 21 shows SDS-PAGE of CLPs with SIV VP6 - Lane 1 only CLPs; Lanes 2, 3 and 4 with different amounts of CLPs with SIV VP6; Lane 5 only SIV VP6.
  • a plasmid containing a chimeric preS 2 ⁇ VP7 gene (Fig. 1) was generated by manipulating an EcoRI-Xhol fragment derived from the ayw subtype of hepatitis B virus (HBV) (8, 9) into the amino terminus of BTV-10 VP7 DNA in a pAcYMl-based transfer vector (pAcBTV10.7) so that it was under the control of the polyhedrin promoter (10, 11). The orientation of the chimeric gene in the transfer vector was confirmed by sequence analysi ⁇ (12). To generate a recombinant virus, monolayer ⁇ of S.
  • frugiperda cell ⁇ were co-tran ⁇ fected with the recombinant tran ⁇ fer vector and AcRP23-lac2 DNA in the pre ⁇ ence of lipofectin (13, 14).
  • Progeny viru ⁇ es with a lacZ-negative phenotype were plaque purified and a recombinant AcBTV-preS ⁇ viru ⁇ was recovered and a high titered virus stock prepared.
  • GCGGGATCCCCTCAGACCCGGGGACACTATCGCCGCA was employed using the polymerase chain reaction to mutate the 5' coding region of the BTV VP7 tran ⁇ fer vector (15) in order to introduce upstream BamHI, Sbal and Smal sites. Since the BTV VP7 transfer vector also contains a down ⁇ tream BamHI site, the modified vector wa ⁇ dige ⁇ ted with BamHI and in ⁇ erted into pAcYMl (11).
  • the product wa ⁇ then dige ⁇ ted with Xbal and Smal and ligated to an EcoRI-Xhol fragment derived from the ayw ⁇ train of HBV (8) modified at both end ⁇ with adapter ⁇ (underlined) to provide a 5' overhang complimentary to a cut Xbal ⁇ equence and a 3' blunt end.
  • the ⁇ equence of the amino terminu ⁇ of the derived chimeric gene i ⁇ ⁇ hown in Fig. 1.
  • the ⁇ ynthe ⁇ i ⁇ of proteins by recombinant AcBTV7-preS viru ⁇ wa ⁇ investigated by infecting monolayers of S. frugiperda cell ⁇ with 5 plaque forming unit ⁇ (PFU) of AcBTV7-preS 2 per cell.
  • Cell ⁇ were harve ⁇ ted at 48 h po ⁇ t-infection, ly ⁇ ed a ⁇ de ⁇ cribed previou ⁇ ly (6) and extract ⁇ analyzed by 10% SDS-polyacrylamide gel electrophore ⁇ i ⁇ (SDS-PAGE).
  • the S. frugiperda cell ⁇ were infected at a m.o.i. of 5 PFU per cell with AcBTWP-preS 2 (lane 1), or AcBTVlO.7 (lane 2), or AcNPV (lane 3) or mock-infected (lane 4).
  • Cell lysates were proces ⁇ ed as described. Proteins were separated by 10% SDS-PAGE and (A) stained with Coomassie blue, or (B) were electroblotted onto an Immobilon membrane and reacted with rabbit anti-preS-, or (C) blotted and reacted with rabbit BTV-10 antiserum.
  • Bound antibody wa ⁇ detected u ⁇ ing an alkaline pho ⁇ phatase conjugate.
  • Protein molecular weight markers (KD) are shown in the left hand lane of (A) . The po ⁇ itions of the AnNPV polyhedrin (P), preS_-VP7 and VP7 protein ⁇ are indicated.
  • S. frugiperda cells were infected with a dual recombinant baculovirus (AcBTV17.3-10.7) that expres ⁇ e ⁇ VP3 and VP7 (6) at a multiplicity of infection (m.o.i.) of 2 PFU per cell and the AcBTV7-preS 2 viru ⁇ at a m.o.i. of either 2 or 8 PFU per cell infected.
  • Infected cell ⁇ were harvested at 3 days p.i., lysed and CLPs purified by centrifugation as previously described (6).
  • the amount of the chimeric VP7 in the CLPs was dependent on the m.o.i. of the AcBTV7-preS 2 recombinant virus used in the coinfection.
  • the preS 2 ⁇ VP7 protein content relative to VP7 was significantly less than when AcBTV7-preS 2 was employed at a m.o.i. of 8 (Fig. 3A) .
  • the amount of the chimeric VP7 was estimated from the stained gel to be ca 20% the amount of authentic VP7.
  • Fig. 3B HBV preS 2 peptide anti ⁇ erum
  • CLPs compo ⁇ ed of VP3 and VP7 (lane 1), or VP3, VP7 and preS 2 -VP7 (lanes 2,3) were ⁇ ynthe ⁇ ized in in ⁇ ect cell ⁇ .
  • Purified CLP ⁇ were purified by discontinuous sucrose gradient centrifugation. Proteins were separated by 10% SDS-PAGE and stained with Coomassie blue (A), or were elctroblotted onto an Immobilon membrane and reacted with rabbit anti-preS 2 serum (B).
  • preS 2 ⁇ VP7 protein on the particles was analyzed by immuno-electron microscopy u ⁇ ing gold-labelled anti-HBV preS 2 serum.
  • the gold particles were located on the outer surface of the CLP ⁇ (purified CLPs obtained from coinfection of in ⁇ ect cell ⁇ with AcVP7-preS 2 ), indicating that the preS 2 ⁇ equences were exposed on the ⁇ urface of the particles.
  • Fig. 5 shows in particular SDS 10% PAGE (A) and Western immunoblot (B) of:
  • GST glutathione S-transfera ⁇ e
  • C 1:Western immunoblot with 1 HBVsAg po ⁇ itive patient serum; L,Large (preS 1 *-PreS 2 -S) HBV ⁇ urface antigen. M, medium (pre S--S) HBV ⁇ urface antigen; and
  • Chimeric CLP ⁇ were additionally produced from BTV VP3 and a chimeric protein compri ⁇ ing BTV VP7 having a 30 amino acid sequence at it ⁇ N-terminu ⁇ derived from the HIV-1 V3 loop.
  • Photograph B illustrates the interaction of anti-HIV-1 V3 sera with:
  • chimeric CLP ⁇ show an interaction with both anti-BTV and anti HIV-1 V3 ⁇ erum wherea ⁇ native BTV CLP ⁇ ⁇ how no interaction to anti HIV-1 V3 sera.
  • VLPS were also constructed from (i) BTV VP3,
  • a chimeric protein comprising BTV VP7 having a 30 amino acid ⁇ equence at it ⁇ N-terminu ⁇ derived from the HIV-1 V3 loop, (iii) VP2, and (iv) VP5
  • VLP VLP ⁇ derived from BTV VP2, BTV
  • chimeric VLPs show an interaction with anti HIV-1 V3 ⁇ erum wherea ⁇ native BTV VLP ⁇ show an interaction to anti HIV-1 V3 sera.
  • the mobility of chimeric VP7 i ⁇ however, lower than that of native VLP ⁇ .
  • Oligonucleotide duplex coding for Clostridium difficle Toxin A wa ⁇ cloned on the amino-terminus of VP7 gene (see Fig. 7). A recently developed dual vector coding for VP3 and VP7 was used for cloning the epitope in this vector. VP3 gene is expres ⁇ ed under the control of the polyhedrin promoter, while VP7 gene with Smal and Spel (compatible with Xbal) cloning ⁇ ite ⁇ i ⁇ placed under the control of polyhedrin promoter.
  • S. frugiperda cell ⁇ were infected with recombinant baculoviru ⁇ expre ⁇ ing VP3 and chimeric decapeptide VP7.
  • CLP ⁇ were produced, purified and inve ⁇ tigated by PAGE, Western blot and electron microscopy. On the PAGE of chimeric CLPs and CLP ⁇ , it could be ⁇ een that the chimeric decapeptide VP7 i ⁇ larger than unmodified VP7 ( ⁇ ee Fig. 8).
  • BLV Bovine Leukemia Virus
  • Bovine leukemia virus (BLV) epitopes were placed upstream of the amino-terminus of VP7. Cosynthesis of the fusion protein with BTV VP3 using recombinant baculovirus did not produce core-like particles (CLPs). However, chimeric CLPs containing the fu ⁇ ion protein were produced when both unmodified BTV VP7 and the fu ⁇ ion protein were co ⁇ ynthe ⁇ ized along with BTV VP3.
  • BLV Bovine leukemia virus
  • BLV gp51 epitopes used in this study are listed in Table 1.
  • Tran ⁇ fer vectors for the recombinant baculoviruse ⁇ were produced by placing annealed oligonucleotide ⁇ of BLV gp51 epitope ⁇ equences (Table 2) into the amino-terminus of BTV 10 VP7 cDNA in pAcBTV10.7 (28) or pAcVC3.BTV 10.7.BTV17.3 (29) plasmid ⁇ .
  • the IIP test used was similar to that described by Sugiyama et al, (1989) Res. Vet. Sci. 46: 283-285. Briefly, Sf cell ⁇ infected with the recombinant baculoviru ⁇ in microtitreplate ⁇ were fixed with methanol, covered with blocking ⁇ olution (5% Skim milk in pho ⁇ phate-buffered saline), then probed with antibody followed by peroxidase-protein A (Bio Rad) . Bound peroxida ⁇ e-protein A wa ⁇ vi ⁇ ualized using o-phenylenediamine.
  • Infected Sf cell ⁇ and CLPs were analyzed by SDS-PAGE after SDS-mercaptoethanol treatment. Proteins were Western blotted to Immunobilon membrane (Millipore Corp. ) which were then soaked overnight in blocking solution, prior to probing with anti-VP7 or anti-pp sera followed by peroxidase-protein A, and detection using ECL sy ⁇ tem (Amersham) .
  • E frugiperda cell ⁇ (ILPB-Sf21) and recombinant baculoviruses were propagated as described previously (25, 28). Standard procedures were used for plasmid DNA manipulations (27). Polymerase chain reaction (PCR) with subsequent proteinase K dige ⁇ tion wa ⁇ performed a ⁇ de ⁇ cribed (30). For con ⁇ truction of recombinant baculoviruses the transfer pla ⁇ mid vector ⁇ containing foreign gene ⁇ were lipofected with B ⁇ u36I cut Bac PAk6 DNA, white plaque ⁇ were ⁇ elected and purified by two sequential plaque a ⁇ ay ⁇ (31). Purification of chimeric CLP ⁇ , SDS-polyacrylamide gel electrophoresi ⁇ , We ⁇ tern blot and electron micro ⁇ copy were done a ⁇ de ⁇ cribed before (28). Amino terminal deletion ⁇
  • VP7 vector u ⁇ ed in our previou ⁇ ⁇ tudie ⁇ utilize ⁇ amino terminu ⁇ of VP7 for attachment of foreign epitopes, though epitopes as large as 50 aa can be expressed on the surface of chimeric CLPs, the vector sy ⁇ tem u ⁇ ually need ⁇ co-infection with ⁇ ome unmodified VP7. Otherwise in most cases particles are not formed or are unstable.
  • amino terminal deletions of VP7 were constructed in order to extent the capacity of VP7 as a vector. If amino terminal sequence ⁇ of VP7 are not nece ⁇ ary for the formation of CLPs, then they can be substituted for other amino acid sequence ⁇ (foreign epitope ⁇ ) and the larger ⁇ equences (more than 50 aa) can be inserted.
  • Bglll Direct primers M E I L G I MEI GGCAGATCTACCATG.GAA.ATT.TTG.GGG.ATA.G (29 aa Bglll deletion) M A Q R N E M MAQ GGCAGATCTACCATG.GCA.CAA.AGA.AAT.GAG.ATG.T 55 aa Bglll deletion)
  • PCR fragments obtained with these primer ⁇ were treated with proteina ⁇ e K, phenol and ethanol precipitated. After dige ⁇ tion with Bglll restriction endonuclease PCR fragment ⁇ were cloned into BamHI ⁇ ite of pAcYMl baculovirus expre ⁇ ion vector (32). Recombinant viru ⁇ e ⁇ were obtained u ⁇ ing BacPAK6 linearized baculovirus DNA (31). Expre ⁇ sion of amino terminus truncated VP7 protein ⁇ was verified on the Coomas ⁇ ie blue stained polyacrylamide gel ⁇ . A ⁇ expected, truncated VP7 proteins had molecular weights 24 kD(29 a ⁇ deletion) and 30 kD (55 a ⁇ deletion) .
  • CLP ⁇ For production of CLP ⁇ , S. frugiperda cell ⁇ were co-infected with recombinant baculoviru ⁇ expre ⁇ ing VP3 and recombinant baculoviru ⁇ e ⁇ expre ⁇ ing either VP7 (29 aa deletion), VP7 (55 aa deletion) or VP7 as a positive control.
  • Cell ⁇ were ly ⁇ ed 48 hr po ⁇ t-infected and CLP ⁇ were purified a ⁇ de ⁇ cribed previously (28).
  • the aim was to determine the regions within the VP7 molecule, that are able to carry extra sequences, since such regions could be advantageous for expression of conformational epitopes. Development of ⁇ uch vector ⁇ are e ⁇ ential as that the majority of immunogenic epitopes is conformational.
  • Hydrophilic regions of VP7 have been targeted as, in general, hydrophobic regions are needed for intra-inter molecular interactions.
  • Two BstXI site ⁇ (po ⁇ ition 105 and 937 bp) were u ⁇ ed to in ⁇ ert amino acid sequences into VP7. Both site ⁇ are ⁇ ituated in parts of the VP7 gene coding for hydrophilic region ⁇ of VP7.
  • the VP7 tertiary structure i ⁇ known. Amino acid insertion ⁇ into it ⁇ hould be ⁇ ituated in the loop between A and B ⁇ -sheets, therefore X-ray crystalographic studies are required. Therefore it can be expected that insertions into this site should not disturb the tertiary structure of VP7.
  • oligonucleotide duplexe ⁇ coding for four amino acid ⁇ each were ⁇ ynthe ⁇ ized ( Figure 13).
  • pUC4K-BTV-10 S7 pla ⁇ mid containing S7 gene cloned in the BamHI ⁇ ite of pUC4K vector was digested with B ⁇ tXI re ⁇ triction endonuclease and p6/p7 and p8/p9 oligonucleotide duplexe ⁇ were ligated into it ⁇ eparately.
  • Recombinant baculoviru ⁇ e ⁇ expres ⁇ ing VP7 variant ⁇ with in ⁇ ertion ⁇ were produced a ⁇ de ⁇ cribed above.
  • S. frugiperda cell ⁇ were coinfected with recombinant baculoviru ⁇ e ⁇ expre ⁇ sing VP3 and VP7 with insertions.
  • CLPs were produced with unmodified VP7, but not with VP7 variants carrying 4 aa insertion ⁇ .
  • Dual baculoviru ⁇ expre ⁇ ion vector pAcUW3 wa ⁇ used for the expres ⁇ ion of both A and B subunit ⁇ of Helicobacter pylori u ⁇ ing ⁇ ingle baculoviru ⁇ (34).
  • Polymera ⁇ e chain reaction (PCR) wa ⁇ performed a ⁇ de ⁇ cribed (30).
  • PCR polymera ⁇ e chain reaction
  • DNA, white plaque ⁇ were selected and purified by two ⁇ equential plaque a ⁇ ay ⁇ (31). Polyacrylamide gel electrophore ⁇ i ⁇ were done as described before (28).
  • Genes coding for the Helicobacter pylori urease subunits A and B were produced by PCR, using 2.7 kb Taql clone (W. Thomas) a ⁇ a template.
  • PCR fragment ⁇ containing structural genes coding for the urease subunit ⁇ were cloned in the pAcUW3 vector, urea ⁇ e A ⁇ ubunit ⁇ in the BgHI ⁇ ite, under the control of the polyhedrin promoter.
  • Orientation of PCR fragment ⁇ in the pAcUW3 A, B. plasmid was established using Hindlll restriction endonuclease.
  • a chimeric protein with a T-helper epitope from the gag gene of SIV (41 to 62) amino acid) on the carboxy terminu ⁇ (Hindlll site by removing 23 amino acids) of VP6 protein of BTV was constructed.
  • the resulting protein was encapsidated in the core-like particles (CLP ⁇ ).
  • the SIVgag epitope was ⁇ ynthe ⁇ i ⁇ ed by PCR u ⁇ ing the ⁇ tandard protocol.
  • the cloned SIVgag gene wa ⁇ used as the template and the following nucleotides as primers: 1. Forward primer
  • the chimeric VP6 SIV gene was excised from pUC19 by digestion with BamHI and cloned at the BamHI ⁇ ite by the baculoviru ⁇ tran ⁇ fer vector pAcYMI. The orientation wa ⁇ checked by ⁇ equencing. Preparation of recombinant baculovirus expressing SIV epitope with BTV VP6
  • a monolayer of Sf21 cells was co-transfer vector and B ⁇ u361 dige ⁇ ted baculovirus bakPac6 DNA.
  • the supernatant containing the progeny viruses was collected at 60 hr. p.i. and the recombinant viruse ⁇ were plaque purified (white plaques) against wild types (blue plaques) .
  • the cells were co-infected with a dual recombinant baculovirus expre ⁇ sing VP3 and VP7, and SIV VP6 recombinant baculovirus.
  • the CLPs were purified at 48 hr p.i.
  • the vaccine ⁇ of the invention in are formulated by method ⁇ known in the art, ⁇ uch a ⁇ for example by ⁇ imple mixing.
  • the vaccine ⁇ are employed in amounts readily determined by one of ordinary ⁇ kill.
  • a ⁇ uitable do ⁇ age i ⁇ in the range of 10 ⁇ g to 100 mg, for example 50 ⁇ g to 50 mg. Similar dosages will be applicable for children.
  • Carrier sy ⁇ tems for humans may include enteric relea ⁇ e cap ⁇ ule ⁇ protecting the antigen from the acidic environment of the stomach.
  • Adjuvants may al ⁇ o be employed.
  • a ⁇ uitable mucosal adjuvant is cholera toxin. Others which may u ⁇ ed are non-toxic derivative ⁇ of cholera toxin.
  • the amount of adjuvant employed depend ⁇ on the type u ⁇ ed. Typically, when cholera toxin i ⁇ employed, it is used in an amount of about 5 ⁇ g to 50 ⁇ g, e.g. 10 ⁇ g to 35 ⁇ g.
  • Suitable carriers are enteric capsule ⁇ and polylactide-glycolide micro ⁇ phere ⁇ .
  • Suitable diluent ⁇ are 0.2N NaHCO, and/or ⁇ aline.
  • Preferred mode ⁇ of administration are orally, nasally, rectally or ocularly.
  • Oral administration can provide delivery to other G.I. muco ⁇ a including intestinal mucosa.
  • the vaccine may be administered to mucosal surface ⁇ a ⁇ an aero ⁇ ol, ⁇ u ⁇ pen ⁇ ion, cap ⁇ ule, and/or ⁇ uppo ⁇ itory. The method of administration will be readily apparent to a per ⁇ on of ordinary ⁇ kill in this art.
  • BTV structural protein chimeras have been constructed based on VP7 containing well-studied immunogenic region ⁇ of variou ⁇ foreign viral antigen ⁇ (e.g., rabie ⁇ viru ⁇ glycoprotein G, hepatiti ⁇ B viru ⁇ preS ? region, HIV and SIV gag and env protein ⁇ ).
  • variou ⁇ foreign viral antigen ⁇ e.g., rabie ⁇ viru ⁇ glycoprotein G, hepatiti ⁇ B viru ⁇ preS ? region, HIV and SIV gag and env protein ⁇ .
  • a 10 amino acid re ⁇ idue ⁇ equence repre ⁇ enting an immunogenic region of rabie ⁇ G protein wa ⁇ introduced to the amino terminus of VP7 and the chimeric protein was expres ⁇ ed by a recombinant baculoviru ⁇ and incorporated into CLP ⁇ and VLP ⁇ on co-expre ⁇ ion with other BTV protein ⁇ .
  • the particle ⁇ ha been used to elicit immune re ⁇ pon ⁇ e in mice and ⁇ hown to produce sera that recognize, by We ⁇ tern blot analy ⁇ is, authentic rabies G protein.
  • a chimeric VP7 protein containing most of the hepatiti ⁇ B viru ⁇ preS ? region (amino acid residues 1-48) upstream to, and co-linear with the amino-terminus of VP7 protein (preS 2 -VP7) wa ⁇ expressed and incorporated into the CLPs in the presence of authentic VP7 and VP3. Both VP7 proteins were incorporated into CLP ⁇ .
  • the ratio of preS ? -VP7 incorporated into CLP ⁇ wa ⁇ influenced by the expre ⁇ ion level of authentic VP7. Immunoelectron micro ⁇ copy of the chimeric particles indicated that the preS 2 epitope was exposed on the surface of the CLP ⁇ .
  • chimeric VP7 e.g., the VP3 loop of HIV-1 env, the amino acid re ⁇ idues 41-60 of SIV gag, and the amino acid residues 161-180 of SIV gag protein
  • Each of these epitope ⁇ were fu ⁇ ed with the amino-terminu ⁇ of BTV VP7 protein and expre ⁇ ed by recombinant baculoviruses.
  • Each recombinant virus was then used to infect insect cells together with a ⁇ econd recombinant viru ⁇ expressing the BTV VP3 protein in order to form CLPs.
  • a ⁇ mall epitope e.g. the 10 amino acid ⁇ equence repre ⁇ enting a rabie ⁇ G sequence
  • wa ⁇ incorporated into the VP7 amino terminu ⁇ , CLP ⁇ were formed on co-expre ⁇ ion with VP3 alone.
  • u ⁇ ing chimeric VP7 including an N-terminal ⁇ equence derived from the hypervariable region of the HIV V3 loop (30 amino acid residues) CLPs can be formed in the absence of authentic VP7 protein.
  • the VP7 of BTV exists on the ⁇ urface of CLPs as trimers. Recent analyses have shown that when insufficient VP7 is made in co-infections with vectors that synthesize large quantities of VP3, incomplete CLPs are produced, CLPs that lack some of the surface arrangement of VP7. It is po ⁇ ible that VP7 is added sequentially to the VP3 subcore, fir ⁇ t to po ⁇ ition ⁇ that stabilize the structure and ⁇ econd to po ⁇ ition ⁇ that complete the CLP ⁇ urface ⁇ tructure. By thi ⁇ model, when a chimeric VP7 i ⁇ unable to produce a CLP with VP3 alone, ⁇ upplementation with unmodified VP7 protein allow ⁇ incorporation of the chimeric protein.
  • the present invention is concerned with the expression of chimeric VP7 proteins containing 48 amino acid residues of the hepatitis B viru ⁇ (HBV) pre-S 2 region, 30 amino acid residue ⁇ of the HIV-1 V3 loop, and 10 amino acids of rabie ⁇ viru ⁇ G-protein.
  • the chimeric VP7 protein ⁇ were expre ⁇ ed in baculoviru ⁇ together with native BTV structural proteins to produce chimeric CLPs and VLP ⁇ .
  • VP7/HBV pre-S_ the protein, although not included into CLPs when expre ⁇ sed with VP3, was included into CLPs when co-expressed with VP3 and VP7, indicating that the particles can accommodate various forms of VP7.
  • the biological and immunological characteri ⁇ tic ⁇ of the ⁇ e particle ⁇ have been analyzed.
  • the HBV epitope ⁇ were localized to the surface of the CLPs as demonstrated using immunogold electron microscopy.
  • the chimeric protein formed BTV corelike particles (CLPs) in S. frugiperda cells only when the cells were co-infected with thi ⁇ recombinant viru ⁇ and a recombinant baculoviru ⁇ that expre ⁇ ses unmodified VP7 and VP3 of BTV.
  • the ratio of preS 2 -VP7 incorporated into CLP ⁇ wa ⁇ influenced by the relative multiplicities of infection of the two viru ⁇ e ⁇ .
  • Immuno-electron micro ⁇ copy of the chimeric particles indicated that the preS 2 epitope was exposed on the surface of the CLPs.
  • insect cells were co-infected with the preS 2 ⁇ VP7 recombinant virus and a baculovirus vector that ⁇ ynthe ⁇ ized only the VP3 protein, no CLP ⁇ were identified.
  • the ⁇ ynthe ⁇ is of high level ⁇ of BTV chimeric CLPs offers a novel approach for presenting large epitopes.
  • the immunogenity of foreign epitope ⁇ presented by ⁇ uch CLPs was demonstrated in mice.
  • the ⁇ tructure of typical VLP ⁇ and CLP ⁇ can allow additional antigen ⁇ to be incorporated, for example in a hollow central region. Thu ⁇ multivalent vaccines can be produced utilizing the procedures described herein.
  • CLPs and VLPs produced according to the invention offer several particular advantages over other system ⁇ . Fir ⁇ t, large quantitie ⁇ can be produced, e ⁇ pecially when use i ⁇ made of the expre ⁇ sion capabilities of baculovirus vectors (e.g. the potential for production at 20-30 mg per liter culture, the potential for production in serum-free medium, and stability to freeze-drying) .
  • CLPs and VLPs can be purified using a one-step generic protocol based on the physical propertie ⁇ of the particle (gradient centrifugation of cell ly ⁇ ate ⁇ ).
  • they can be produced in a form which i ⁇ ⁇ ub ⁇ tantially devoid of any detectable amount ⁇ of foreign e.g.
  • in ⁇ ect, or baculoviru ⁇ proteins and of RNAs or DNA ⁇ can be used which are gentle enough to maintain the morphological structure of the particles in their native conformation ⁇ .
  • the particle ⁇ can be made in a form which do not replicate although they can efficiently attach to and be taken up by cell ⁇ .
  • CLPs and VLPs, especially those based on BTV can tolerate a wide range of additional protein ⁇ equence ⁇ without disruption, allowing multiple epitopes to be accommodated.
  • VLP ⁇ can be produced which have inherent propertie ⁇ of inducing both B cell and T cell re ⁇ pon ⁇ e ⁇ in vertebrate ho ⁇ t ⁇ .
  • CLPs and VLPs have been developed which can deliver multiple peptide component ⁇ repre ⁇ enting viral epitopes in order to elicit protective immunity.
  • the CLP ⁇ and VLP ⁇ , especially those of BTV, are large multiprotein structures.
  • VP7a and VP7b alternative protein forms of the structural proteins
  • VP7a and VP7b alternative forms of these protein ⁇
  • antigens e.g., VP2 and/or VP5 and/or VP7
  • Thi ⁇ feature ha ⁇ important implication ⁇ , e.g. to decrea ⁇ e the chance of non-re ⁇ pon ⁇ ivene ⁇ : vaccines designed to elicit immunity should preferably not be based on a single viral sequence or antigen but ⁇ hould include a ⁇ many immunogenic sequences as feasible.
  • VLP ⁇ ba ⁇ ed on alternative BTV ⁇ erotypes can al ⁇ o be employed for ⁇ ucce ⁇ ive immunization ⁇ in order to evade anti-BTV re ⁇ ponses elicited in a primary vaccination.
  • CLPs and VLPs from baculovirus vectors suggest that this sy ⁇ tem may be adopted a ⁇ a carrier ⁇ y ⁇ tem in which multiple foreign antigens can be presented to the immune systems to induce both cellular and humoral immunity.
  • foreign antigens can be expres ⁇ ed a ⁇ epitope ⁇ on protein component ⁇ of CLP ⁇ and VLP ⁇ in a manner which enable ⁇ the epitope ⁇ to be located in an internal ⁇ ite in the CLPs and VLPs.
  • Thi ⁇ can protect the foreign antigen ⁇ from proteolysi ⁇ and/or antibody attack until it reaches a desired location. This may for example be achieved with a chimeric VLP in which the VP7 i ⁇ in chimeric form.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Antigens in particulate form are provided wherein chimeric antigens having foreign epitopes are presented on or within virus-like particles (VLPs) or virus core-like particles (CLPs). The VLPs and CLPs are immunogenic and are useful in producing vaccine formulations.

Description

MULTIPLE PARTICULATE ANTIGEN DELIVERY SYSTEM
This invention relates to antigens in particulate form, especially antigens in the form of virus-like particles or virus core-like particles. The invention particularly relates to chimeric antigens wherein foreign epitopes are presented on or within virus-like particles or virus core-like particles.
BACKGROUND OF THE INVENTION
Viruses generally are composed of a plurality of different proteins assembled together in a regular arrangement together with DNA or RNA. For viruses that lack a lipid envelope, the proteins are often arranged in a layered or concentric manner with certain proteins cooperating to form the outer coat or capsid and others forming the so-called core or inner capsid.
In many virus species, virus proteins are capable of assembling in the absence of nucleic acid to form so-called virus-like particles or VLPs. Similarly, the proteins which normally cooperate together with nucleic acid to form the virus core can assemble in the absence of nucleic acid to form so-called core-like particles (CLPs). As used herein, the terms "virus-like particles" and "core-like particles" will be used in the above sense to designate assemblages of virus proteins (or modified or chimeric virus proteins) in the absence of virus genomic nucleic acid.
The provision of immunogenic epitopes in entities which are in particulate form is highly desirable as such forms can be especially useful in for example the development of vaccines for oral or other mucosal routes of administration. However, relatively few useful immunogenic epitopes can readily be produced in particulate form wherein the epitopes remain immunogenic. The development of particulate vector systems for the presentation of immunogenic epitopes provides a powerful approach for the delivery of antigens. Various types of particles have been used to present foreign epitopes, including particles formed from the hepatitis B virus (HBV) surface or core antigens, polioviruεes and yeast Ty-particleε (1-5).
VLPs and CLPs are examples of particulate antigens that possess immunogenic epitopes. These may often be located at or adjacent to the particle surface, although epitopes may also be located internally. Further, VLPs and CLPs are sufficiently stable and resistant to degradation to enable them to have potential use as vaccines when administered by the oral, respiratory or other mucosal routes, the latter property no doubt being associated with the fact that many viruses in native form are infectious orally. Examples of such viruses are members of the family Reoviridae.
However, attempts to modify native VLPs and CLPs in order to incorporate foreign epitopes have been fraught with difficulties as a result of several factors. Firεt of all, it is often the case that incorporation of foreign proteins of protein fragments into VLPs or CLPs inhibits particle formation. Furthermore, even if particle formation is possible, it iε uncertain whether the desired foreign epitope will- be immunogenic. For example, it may be located in a site where the foreign epitope is incapable of assuming its natural conformation.
It haε recently been reported that when the two major inner capεid proteinε (VP3 and VP7) of bluetongue virus (BTV, Orbivirus genus, Reoviridae) are synthesized in insect cellε by a dual recombinant baculovirus, viral core-like particles (CLPs) are formed (6). These particles can be isolated by one-step sucrose gradient centrifugation or by salt precipitation.
It has also been found that expression of the two major outer capsid proteinε (VP2 and VP5) together with VP3 and VP7 uεing εuitable recombinant baculoviruεes resultε in the synthesis of VLPs. Further, expreεεion of different combinations of minor internal proteins VPl, VP4 and VP6, both with the components of CLPs (VP3 and VP7) or VLPs (VP2, VP5, VP3, VP7), results in the inclusion of VPl, VP4 and/or VP6 into CLPs or VLPs respectively.
Further, the εynthesiε of CLPs can be obtained by co-expression of VP3 and VP7 species representing different serotypes of BTV or other orbiviruses such as epizootic hae orrhagic disease virus (EHDV) VP3 and BTV VP7. Further the syntheεiε of VLPs can be obtained with genes representing different BTV εerotypeε.
DESCRIPTION OF THE INVENTION
The present invention provides VLPε and CLPs which are immunogenic and especially such VLPs and CLPs which are useful in vaccine formulation. More particularly, the preεent invention provides genetically engineered, multi-component, virus-like particles (VLPs) and virus core-like particles (CLPε) aε vaccine delivery systems for multiple immunogens representing viruses, bacteria and bacterial toxins that are responsible for human diseaεeε (e.g. Hepatitiε B, HIV, Reεpiratory Syncytial Viruε, Cloεtridium difficile, Bovine Leukemia Virus, Helicobacter pylori, etc.),
According to one aspect of the present invention, there iε provided an antigen in particulate form compriεing a plurality of proteins capable of asεembly in cooperation with one another into virus-like particles (VLPs) or viruε core-like particles (CLPs), wherein the particles include firεt and second different proteins each of which compriseε amino acid sequences derived respectively from firεt and εecond native proteinε of a selected viruε εpecieε and wherein at leaεt one of the first and second proteins is chimeric and compriεes an amino acid sequence derived from a foreign protein other than εaid firεt or εecond native protein.
According to another aεpect, the invention provideε a method of producing chimeric VLPε or CLPε comprising at leaεt one non-native protein, in which the VLPs or CLPε are asεe bled from a plurality of different proteins including native virus proteins and the non-native protein. The non-native protein comprises an amino acid sequence derived from a foreign protein and an amino acid εequence derived from a native viruε protein.
According to a further aspect, the invention provides a vaccine composition compriεing an effective amount of an antigen of the invention, in asεociation with a therapeutically acceptable carrier or diluent.
The invention alεo provideε a method of inducing a protective immunogenic reεponse in a host in need of treatment, wherein an immunologically effective amount of an antigen according to the invention is administered to the host. The antigen according to one aspect may be administered to a mucosal surface of said hoεt. Suitably, the antigen is administered orally.
The present invention is based upon the surpriεing discovery that the above technology can be adapted to allow the formation of CLPε and VLPs which can be used to present foreign epitopes. This is baεed on the finding by the preεent inventor that the VP7 protein iε located on the outer surface of the CLPs with VP3 forming an inner icosahedral subcore. Introduction of a 14 amino acid sequence representing an immunogenic region of rabieε G protein to the amino terminus of VP3 results in expression of chimeric protein and the formation of CLPs when co-expressed with VP7.
Further research has now demonstrated the potential of VLPs and CLPs aε a means for constructing useful antigenic and immunogenic particles. Thus, chimeric BTV VP7 protein containing at least 48 foreign amino acids can be incorporated into CLPs and VLPs. More specifically, it has been determined that when the rabies 14 amino acid residues or amino acid residues 1-48 of the hepatitis B virus preS_ region are incorporated into the amino terminus of VP7, not only are the chimeric proteins expressed in infected cells but also they can be incorporated into CLPs on co-expression with VP3.
Likewise, it has been determined that when 30 amino acids representing the V3 loop of the envelope protein of Human Immunodeficiency Viruε Type 1 (HIV-1) are incorporated into the amino terminus of BTV VP7, chimeric VP7 is εyntheεized and incorporated into CLPs on co-expression with BTV VP3.
Clostridium difficle is the causative agent of colitis in humans. Toxin A plyε an important role in the pathogeniεiε of thiε diεeaεe. The decapeptide TIDGKKYYFN iε repeated εeveral timeε in Toxin A. An oligonucleotide duplex coding for Cloεtridium difficle decapeptide Toxin A waε cloned on the amino terminus of the VP7 gene using a dual vector coding for VP3 and VP7 (VP3 gene iε expressed under the control of the pclyhedrin promoter while VP7 gene with Smal and Spel (compatible with Xbal) cloning siteε iε placed under the control of polyhedrin promoter. S_. frugiperda cells infected with recombinant baculovirus expresεed VP3 and chimeric decapeptide VP7 CLPε.
Bovine Leukemia Virus (BLV) epitopes placed upstream of the amino terminus of BTV VP7 and cosynthesiεed with BTV VP3 using recombinant baculovirus did not produce CLPs. However, chimeric CLPs containing the fusion protein were produced when both unmodified BTV VP7 and the fusion protein were cosyntheεiεed with BTV VP3.
Genes coding for the Helicobacter pylori urease εubunitε A and B were produced by PCR and cloned in the pAcUW3 vector. Recombinant baculoviruseε were produced using thiε plasmid. S. frugiperda cells infected with the recombinant baculovirus produced both urease subunits A and B.
Antigens according to the invention which are in the form of CLPε generally comprise two esεential proteinε and one or more further optional proteins, wherein the esεential proteins are virus major inner capsid proteins and the optional proteins are εelected from minor inner capεid proteinε. Preferably, the CLPε compriεe zero, one, two or three further optional virus minor inner capsid proteinε.
Antigenε according to the invention wr:1ch are in the form of VLPε generally compriεe three eεεential proteinε and one or more further optional proteinε, wherein two of the eεεential proteinε are viruε major inner capsid proteins, one of said essential proteins iε a viruε major outer capsid protein, and the optional proteinε are selected from minor inner capεid proteins and major outer capsid proteins. Preferably the VLPε compriεe zero, or one further optional virus major outer capεid proteinε and/or zero, one, two or three further optional virus minor inner capsid proteins.
Antigens in particulate form according to the invention can comprise a plurality of proteins capable of assembly in cooperation with one another into virus core-like particles (CLPs). The antigens include first and εecond different major structural proteins each of which comprises amino acid sequences derived reεpectively from first and second native proteins of a εelected viruε εpecieε or related virus species in the presence or absence of any one or combination of three minor proteins each of which compriseε amino acid εequences derived from the three minor proteins of a selected virus species or related virus specieε. At leaεt one of any of the aforementioned five proteinε iε chimeric and comprises an amino acid sequence derived from a foreign protein other than said native proteins.
Similarly, antigens in particulate form according to the invention can comprise a plurality of proteins capable of asεembly in cooperation with one another into virus-like particles (VLPs). The antigens are characterized by including first, second, third and optionally fourth different major structural proteins each of which compriseε amino acid sequences derived respectively from first, second, third and fourth native proteins of a selected virus species or related virus species in the presence or abεence of any one or combination of three minor proteinε each of which compriεeε amino acid εequenceε derived from the three minor proteinε of the εelected virus specieε or a related viruε species. At least one of any of the aforementioned eight proteins iε chimeric and comprises an amino acid sequence derived from a foreign protein other than the native proteins.
Thus, in the caεe of Reoviridae viruε εpecieε, for example orbiviruεes εuch as BTV, the antigenε in particulate form conεiεting of a CLP can compriεe two essential proteins and one or more further optional proteins, wherein the essential proteins are virus major inner capsid proteins VP3 and VP7 and the optional proteins are εelected from the minor inner capsid proteins VPl, VP4 and VP6. These combinations of proteinε may be depicted as follows:
VP3 + VP7
VP3 + VP7 + VPl
VP3 + VP7 + VP4
VP3 + VP7 + VP6
VP3 + VP7 + VPl + VP4
VP3 + VP7 + VP4 + VP6
VP3 + VP7 + VPl + VP6
VP3 + VP7 + VPl + VP4 + VP6
Similarly, VLPs can comprise three eεεential proteinε and one or more further optional proteins, wherein two of the esεential proteinε are viruε major inner capsid proteins VP3 and VP7, one of the esεential proteinε iε a viruε major outer capεid protein εelected from VP2 and VP5 and the optional proteinε are εelected from minor inner capεid proteinε VPl, VP4 and VP6 and major outer capεid proteinε VP2 and VP5.
Theεe combinations of proteins may be depicted as follows:
VP2 + VP3 + VP7
VP2 + VP3 + VP7 + VPl
VP2 + VP3 + VP7 + VP4
VP2 + VP3 + VP7 + VP6
VP2 + VP3 + VP7 + VPl + VP4
VP2 + VP3 + VP7 + VPl + VP6
VP2 + VP3 + VP7 + VP4 + VP6
VP2 + VP3 + VP7 + VP6 + VP4 + VP6
VP5 + VP3 + VP7
VP5 + VP3 + VP7 + VPl
VP5 + VP3 + VP7 + VP4
VP5 + VP3 + VP7 + VP6
VP5 + VP3 + VP7 + VPl + VP4
VP5 + VP3 + VP7 + VPl + VP6
VP5 + VP3 + VP7 + VP4 + VP6
VP5 + VP3 + VP7 + VP6 + VP4 +VP6
VP2 + VP5 + VP3 + VP7
VP2 + VP5 + VP3 + VP7 + VPl
VP2 + VP5 + VP3 + VP7 + VP4
VP2 + VP5 + VP3 + VP7 + VP6
VP2 + VP5 + VP3 + VP7 + VPl + VP4
VP2 + VP5 + VP3 + VP7 + VP4 + VP6
VP2 + VP5 + VP3 + VP7 + VPl + VP6
VP2 + VP5 + VP3 + VP7 + VP6 + VP4 + VP6
The antigens of the invention may be produced with at leaεt one of the proteinε in native form and the εame protein or proteins additionally being in chimeric form, i.e. incorporating amino acid sequences of a foreign protein. Chimeric antigens in particulate form may be produced according to the invention wherein the amino acid sequence derived from the foreign protein includes an epitope which is recognized by an antibody to the foreign protein. For example, the foreign protein is a protein of a disease-producing organism and the antigen in particulate form is capable of raising protective (e.g. neutralizing) antibodies or cellular immune response in an organism susceptible to the diseaεe. The antigenε of the invention find special utility in the formulation of vaccines.
Chimeric VLPs or CLPs may include one or more of the incorporated major structural proteins in chimeric form. In this form, the CLPs may include (i) a first virus protein in native form, (ii) a second viruε protein in native form, and (iii) one of the first and second viruε proteinε in chimeric form compriεing an amino acid εequences derived from native virus protein and an amino acid sequence derived from a foreign protein.
Similarly, the VLPs may include (i) a first virus protein in native form, (ii) a second virus protein in native form, (iii) a third virus protein in native form and (iv) one of the first and second virus proteinε in chimeric form comprising an amino acid sequences derived from native virus protein and an amino acid sequence derived from a foreign protein.
Chimeric VLPε or CLPε compriεing at least one non-native protein are produced according to the invention by aεεembling the VLPε or CLPs from a plurality of different proteins including native viruε proteinε and the non-native protein. The non-native protein compriεeε an amino acid εequence derived from a foreign protein and an amino acid sequence derived from a native virus protein. The amino acid sequence derived from a foreign protein may be located at the N-terminal end of the chimeric protein, although other arrangements are alεo enviεaged according to the invention, for example wherein the amino acid sequence derived from a foreign protein is inεerted within the sequence of the native protein, or is located at the C-terminal end. It haε been found that locating the amino acid sequence derived from a foreign protein at the N-terminal end of the chimeric protein enableε the foreign epitope to be immunogenic in the eventual VLPε or CLPε.
Conventional techniques of site-directed mutagenesis and gene splicing may be employed in order to construct DNA sequences capable of being expressed as the chimeric protein included as a component of the antigen particles of the invention. Similarly the antigen particles may be aεεembled from their conεtitυent components in a variety of ways. Thuε, for example, the componentε may be produced separately and then εimply combined by mixing solutions of the constituent proteins in a suitable medium. However, it is preferred that the native and chimeric proteins are expressed together so that assembly of the antigen particles can take place without the expressed polypeptide being degraded, modified or otherwise procesεed to a form incompatible with their aεεembly to form VLPε or CLPε. Moεt preferably the conεtituent proteinε are co-expresεed.
Although any suitable expression system may be employed, especially satisfactory results have been obtained using an expresεion εystem which includes a baculovirus expreεεion vector. Thuε, preferably the conεtituent proteins are expressed in insectε or insect cellε.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention will now be deεcribed in more detail with reference to the accompanying drawingε, in which:
Figure 1 shows a recombinant transfer vector containing an HBV preS~ sequence upstream and colinear with BTV VP7;
Figures 2A-2C show SDS PAGE analysiε of proteins produced by AcBTV7-preS2;
Figure 3A-B show SDS-PAGE and Weεtern immunoblot analyεeε of CLPε compoεed of VP3 and VP7 (lane 1) or VP3, VP7 and preS2VP7 (laneε 2 and 3);
Figures 4A-B show immunogold-electron microεcope photographε of purified CLPs;
Figures 5A-C show SDS-PAGE and Western immunoblot analyεes relating to immunogenicity of chimeric CLPs;
Figure 6 is a Western blot analyεiε carried out utilizing anti-BTV and anti-V3 (HIV-1) sera againεt native BTV/BTV VP7, chimeric BTV VP7/HIV-1 V3, CLPs derived from native BTV VP3/BTV VP7 and chimeric CLPε derived from BTV VP3/chimeric BTV VP7/HIV-1 V3;
Figure 7 εhowε the junction between the Clostridium difficile toxin A and the amino terminus of the BTV-10 VP7; Figure 8 εhowε PAGE of CLPε and chimeric CLPs carrying the cloεtridium difficile Toxin A decapeptide;
Figure 9 εhowε a Western blot of CLPs and chimeric CLPε with anti-decapeptide antiεerum.
Figure 10 εhows construction of BLV epitopes and BTV VP7 recombinant proteinε;
Figure 11A and B shows Western blot for expression of recombinant baculoviruses. Recombinant virus-infected Sf cell lysate were blotted on the membrane and reacted with (A) anti-VP7 rabbit serum and (B) anti-pp(142-161) rabbit serum. Lane 1; AcVP3.7. Lane 2; AcVP3.B3-7; AcVP3.Bl-7;
Figure 12 shows SDS-PAGE (A) and Western blot analysis (B) of chimeric CLPs using anti-VP7 rabbit serum (a) and anti-pp (142-161) rabbit serum (b) . Lane 1; Normal CLPs, Lane 2; chimeric CLPs (B3-7);
Figure 13 shows DNA and amino acid sequences of VP7 after insertion of p8/p9 and p6/p7 oligonucleotide duplexes. Both inεertion contain unique PpUMI site (underlined) in order to use it for subsequent cloning of foreign epitopes;
Figure 14 showε the BεXI maps of the initial VP7 gene and the genes with insertions;
Figure 15 shows agarose gel electrophoreεis of BamHI/BstXI digests of initial pUC4K-BTVI-VP7 and the clones with insertions. Fragments smaller than 350 b.p. run out of the gel;
Figure 16 εhowε mutationε of VP7 with creation of cloning εiteε;
Figure 17 εhows restriction endonuciease analysis of mutated VP7 genes with created Bglll and Seal sites; Figure 18 showε PAGE of the lysates of S. fruαiperda cells infected with recombinant baculoviruε expreεsing the Helicobacter pylori urease A and B subunitε;
Figure 19 εhowε Weεtern blot of the lyεateε of S. frugiperda cellε infected with recombinant baculoviruε expreεεing the Helicobacter pylori urease A and B subunitε;
Figure 20 εhowε 10% SDS-PAGE εhowing expreεεion of SIV VP6 in inεect cellε; and
Figure 21 εhows SDS-PAGE of CLPs with SIV VP6 - Lane 1 only CLPs; Lanes 2, 3 and 4 with different amounts of CLPs with SIV VP6; Lane 5 only SIV VP6.
EXAMPLES OF PREFERRED EMBODIMENTS EXAMPLE 1
In this Example, there is described the construction of a chimeric protein containing most of the hepatitis B virus preS, region (amino acid residues 1-48) upstream to, and co-linear with, the amino-terminus of bluetongue virus VP7 protein (preS2-VP7).
A.Plasmid Construction
A plasmid containing a chimeric preS2~VP7 gene (Fig. 1) was generated by manipulating an EcoRI-Xhol fragment derived from the ayw subtype of hepatitis B virus (HBV) (8, 9) into the amino terminus of BTV-10 VP7 DNA in a pAcYMl-based transfer vector (pAcBTV10.7) so that it was under the control of the polyhedrin promoter (10, 11). The orientation of the chimeric gene in the transfer vector was confirmed by sequence analysiε (12). To generate a recombinant virus, monolayerε of S. frugiperda cellε were co-tranεfected with the recombinant tranεfer vector and AcRP23-lac2 DNA in the preεence of lipofectin (13, 14). Progeny viruεes with a lacZ-negative phenotype were plaque purified and a recombinant AcBTV-preS~ viruε was recovered and a high titered virus stock prepared.
An oligonucleotide (5'
GCGGGATCCCCTCAGACCCGGGGACACTATCGCCGCA) was employed using the polymerase chain reaction to mutate the 5' coding region of the BTV VP7 tranεfer vector (15) in order to introduce upstream BamHI, Sbal and Smal sites. Since the BTV VP7 transfer vector also contains a downεtream BamHI site, the modified vector waε digeεted with BamHI and inεerted into pAcYMl (11). The product waε then digeεted with Xbal and Smal and ligated to an EcoRI-Xhol fragment derived from the ayw εtrain of HBV (8) modified at both endε with adapterε (underlined) to provide a 5' overhang complimentary to a cut Xbal εequence and a 3' blunt end. The εequence of the amino terminuε of the derived chimeric gene iε εhown in Fig. 1.
B. Expression Of Pres2~VP7
The εyntheεiε of proteins by recombinant AcBTV7-preS viruε waε investigated by infecting monolayers of S. frugiperda cellε with 5 plaque forming unitε (PFU) of AcBTV7-preS2 per cell. Cellε were harveεted at 48 h poεt-infection, lyεed aε deεcribed previouεly (6) and extractε analyzed by 10% SDS-polyacrylamide gel electrophoreεiε (SDS-PAGE). By compariεon with wild-type AcNPV or AcBTV 10.7 that expreεsed only the 38 kDa VP7 protein (15), a protein of the size expected for the HBV-VP7 chimera (preS2-VP7), 43 kFDa) was identified (Fig. 2A) . Confirmation that the expresεed protein repreεented the preS2 region of HBV waε provided by Weεtern blot εyεtem analyεeε (Fig. 2B) uεing a rabbit antiεerum that had been raiεed to an HBV preS2 peptide (amino acid reεidueε 14-32). Both the modified and unmodified VP7 proteins reacted with antiεera raised to BTV-10 viruε particles (Fig. 2C).
The S. frugiperda cellε were infected at a m.o.i. of 5 PFU per cell with AcBTWP-preS2 (lane 1), or AcBTVlO.7 (lane 2), or AcNPV (lane 3) or mock-infected (lane 4). Cell lysates were procesεed as described. Proteins were separated by 10% SDS-PAGE and (A) stained with Coomassie blue, or (B) were electroblotted onto an Immobilon membrane and reacted with rabbit anti-preS-, or (C) blotted and reacted with rabbit BTV-10 antiserum. Bound antibody waε detected uεing an alkaline phoεphatase conjugate. Protein molecular weight markers (KD) are shown in the left hand lane of (A) . The poεitions of the AnNPV polyhedrin (P), preS_-VP7 and VP7 proteinε are indicated.
C. Assembly Of Antigen Particles
To inveεtigate whether the recombinant protein would aεεemble with BTV-VP3 protein to form CLPε (6), a εuεpenεion culture of S. frugiperda cellε waε co-infected with the AcBTV-preS2 recombinant viruε and AcBTV17.3, a recombinant baculovirus that expresses only VP3 protein (16). The infected cells were harvested, lyεed and analyzed by gradient centrifugation aε deεcribed previouεly (6). Despite the high level of expression of both proteins, no morphological structures were recovered (data not shown). As a control, cellε co-infected with AcBTVlO.7 and AcBTV17.3 yielded CLPε (6, data not εhown) .
In order to determine whether there was any condition in which the chimeric VP7 could be incorporated into particles, S. frugiperda cells were infected with a dual recombinant baculovirus (AcBTV17.3-10.7) that expresεeε VP3 and VP7 (6) at a multiplicity of infection (m.o.i.) of 2 PFU per cell and the AcBTV7-preS2 viruε at a m.o.i. of either 2 or 8 PFU per cell infected. Infected cellε were harvested at 3 days p.i., lysed and CLPs purified by centrifugation as previously described (6).
The protein profiles of the CLPs indicated that the two forms of VP7 were present in both CLP preparations (Fig. 3). However, the amount of the chimeric VP7 in the CLPs was dependent on the m.o.i. of the AcBTV7-preS2 recombinant virus used in the coinfection. At the m.o.i. of 2, the preS2~VP7 protein content relative to VP7 was significantly less than when AcBTV7-preS2 was employed at a m.o.i. of 8 (Fig. 3A) . At the high multiplicity, the amount of the chimeric VP7 was estimated from the stained gel to be ca 20% the amount of authentic VP7. The presence of the chimeric protein in the particles was confirmed by 10% Western blot analysiε using the HBV preS2 peptide antiεerum (Fig. 3B) . In Fig. 3, CLPs compoεed of VP3 and VP7 (lane 1), or VP3, VP7 and preS2-VP7 (lanes 2,3) were εyntheεized in inεect cellε. Purified CLPε were purified by discontinuous sucrose gradient centrifugation. Proteins were separated by 10% SDS-PAGE and stained with Coomassie blue (A), or were elctroblotted onto an Immobilon membrane and reacted with rabbit anti-preS2 serum (B). In lanes 2 and 3 the CLPs came from coinfections of AcBTV17-3, 10-7 (m.o.i. of 2) and AcBTV7-preS2 (m.o.i. = 8, lane 2), or AcBTV17-3, 10-7 (m.o.i. = 2), and AcBTV7-preS2(m.o.i. = 2, lane 3).
The location of preS2~VP7 protein on the particles was analyzed by immuno-electron microscopy uεing gold-labelled anti-HBV preS2 serum. As shown in Fig. 4A, the gold particles were located on the outer surface of the CLPε (purified CLPs obtained from coinfection of inεect cellε with AcVP7-preS2), indicating that the preS2 εequences were exposed on the εurface of the particles. In a control experiment using CLPε derived from AcBTV17.3-10.7, no gold particles were detected (Fig. 4B - CLPs purified from cells infected only with AcBTV17.3-10.7. Bar = lOOnm) . When a cell lysate infected with the AcBTV17.3-10.7 dual recombinant virus waε mixed with a cell lyεate recovered from an AcBTWP7-preS? infection, CLPε were recovered and εimilarly analyzed by immuno-electron microεcopy using gold-labelled preS antiserum. No gold particles were detected on the εurface of the CLPs.
D. Iπtmugenicity Of Chimeric CLPs
To demonεtrate the biological activity of the chimeric CLPε, the immugenicity of these particleε was asεeεsed. Antisera against the purified chimeric CLPs was raised in mice as described previously (17) and the reactivities of the resulting antisera were examined against an expressed E. coli fusion protein (18) containing the pre S2 region (GST-preS2 unpublished data). Figure 5A εhows the Coomaεεie blue εtained gel of insect cellε infected with recombinant baculoviruε-expresεing chimeric pre S2-VP7 protein (lane 1), E. coli cellε expreεεing GST-pre S2, induced (lane 2) and non-induced (lane 3) and the GST of the control E. coli culture.
In Weεtern blot analyεeε, both expressed proteins reacted strongly with the antibody raised against chimeric particles. The high immunogenicity was further evidenced by the reactivity of the apparently unstainable fusion protein band of the non-induced GST-pre S2 with the antibody (in a 1 to 4000 titer).
To demonstrate that the antibody can indeed recognize HBV antigen, similar Western blot analyseε were performed uεing εurface antigen poεitive HBV patient εerum (Fig. 5C) . The poεitive signals against large (pre S.-pre s ?~s) anc medium (preS2~S) surface antigen of HBV confirmed the high immunogenic capability of the chimeric particles.
Fig. 5 shows in particular SDS 10% PAGE (A) and Western immunoblot (B) of:
1: Spodoptera frugiperda cells infected with recombinant baculovirus expresεion pre S„-VP7;
2: E. coli cellε expreεεing pre S2 epitope fuεed with C terminuε of glutathione S-tranεferase (GST-pre-S2) in pGEX-1 vector induced with IPTG (18);
3: the εame as lane 2, without IPTG induction
4: E. coli cells expressing glutathione S-transferaεe (GST); and (C) 1:Western immunoblot with 1 HBVsAg poεitive patient serum; L,Large (preS1*-PreS2-S) HBV εurface antigen. M, medium (pre S--S) HBV εurface antigen; and
2:HBVsAg negative human serum. Antibody dilution 1:4000.
Chimeric CLPε were additionally produced from BTV VP3 and a chimeric protein compriεing BTV VP7 having a 30 amino acid sequence at itε N-terminuε derived from the HIV-1 V3 loop.
Weεtern blot analyεis waε carried out utilizing anti-BTV and anti-V3 (HIV-1) sera against native BTV/BTV VP7, chimeric BTV VP7/HIV-1 V3, CLPs derived from native BTV VP3/BTV VP7 and chimeric CLPε derived from BTV VP3/chimeric BTV VP7/HIV-1 V3. The resulting blotε are shown in Figure 6 wherein Photograph A illustrateε the interaction of anti-BTV sera with:
Lane
VP7 native BTV VP3/BTV VP7
V3-VP7 chimeric BTV VP7/HIV-1 V3
CLP CLPε derived from native BTV VP3/BTV VP7
V3 IN CLP chimeric CLPs derived from BTV VP3 and chimeric BTV VP7/HIV-1 V3. and Photograph B illustrates the interaction of anti-HIV-1 V3 sera with:
Lane
CLP CLPε derived from native BTV VP3/BTV VP7
V3 IN CLP chimeric CLPs derived from BTV VP3 and chimeric ETV VP7/HIV-1 V3.
It can be εeen that chimeric CLPε show an interaction with both anti-BTV and anti HIV-1 V3 εerum whereaε native BTV CLPε εhow no interaction to anti HIV-1 V3 sera.
VLPS were also constructed from (i) BTV VP3,
(ii) a chimeric protein comprising BTV VP7 having a 30 amino acid εequence at itε N-terminuε derived from the HIV-1 V3 loop, (iii) VP2, and (iv) VP5
Alεo referring to Figure 6, Photograph C illuεtrateε the interaction of anti-HIV-1 V3 sera with:
Lane
V3 IN VLP chimeric VLPs derived from BTV
VP2, BTV VP3, chimeric BTV VP7/HIV-1 V3 and BTV VP5. VLP VLPε derived from BTV VP2, BTV
VP3 and BTV VP5. It can be εeen that chimeric VLPs εhow an interaction with anti HIV-1 V3 εerum whereaε native BTV VLPε show an interaction to anti HIV-1 V3 sera. The mobility of chimeric VP7 iε, however, lower than that of native VLPε.
EXAMPLE 2
Expression of Clostridium difficle Toxin A decapaptide using chimeric CLP's was inveεtigated aε followε.
Spodoptera frugiperda(Sf) cellε (ILPB-SF21) and recombinant baculoviruεes were propagated as described previously (25, 26). Standard procedures were used for plasmid DNA manipulations (27). For conεtruction of recombinant baculoviruseε the tranεfer plaεmid vectors containing foreign genes were lipofected with Bεu36.1 cut BacPAK6 DNA, and white plaqueε were εelected and purified by two sequential plaque asεayε. Purification of chimeric CLPε, SDS-polyacrylamide gel electrophoreεiε, Western blot and electron microscopy were done as described before (28).
Oligonucleotide duplex coding for Clostridium difficle Toxin A waε cloned on the amino-terminus of VP7 gene (see Fig. 7). A recently developed dual vector coding for VP3 and VP7 was used for cloning the epitope in this vector. VP3 gene is expresεed under the control of the polyhedrin promoter, while VP7 gene with Smal and Spel (compatible with Xbal) cloning εiteε iε placed under the control of polyhedrin promoter.
S. frugiperda cellε were infected with recombinant baculoviruε expreεεing VP3 and chimeric decapeptide VP7. CLPε were produced, purified and inveεtigated by PAGE, Western blot and electron microscopy. On the PAGE of chimeric CLPs and CLPε, it could be εeen that the chimeric decapeptide VP7 iε larger than unmodified VP7 (εee Fig. 8).
Chimeric VP7, but not unmodified VP7, reactε with anti-decapeptide rabbit antibodieε (see Figure 9). On electron microscopy (uranile acetate stain), chimeric CLPs appear to be unstable, many VP7 spikeε are miεεing, and some particles look like subcore particleε. EXAMPLE 3
Expreεεion of Bovine Leukemia Virus (BLV) epitopes using CLPs was investigated as follows.
Bovine leukemia virus (BLV) epitopes were placed upstream of the amino-terminus of VP7. Cosynthesis of the fusion protein with BTV VP3 using recombinant baculovirus did not produce core-like particles (CLPs). However, chimeric CLPs containing the fuεion protein were produced when both unmodified BTV VP7 and the fuεion protein were coεyntheεized along with BTV VP3.
The sequences of three BLV gp51 epitopes used in this study are listed in Table 1. Tranεfer vectors for the recombinant baculoviruseε were produced by placing annealed oligonucleotideε of BLV gp51 epitope εequences (Table 2) into the amino-terminus of BTV 10 VP7 cDNA in pAcBTV10.7 (28) or pAcVC3.BTV 10.7.BTV17.3 (29) plasmidε.
Table 1. Epitopes in BLV gp51 employed in this study
Epitope BLV gp51 amino acid εequence Comments Bl 98-117(20 residues) Syncytia inhibition B2 169-192 (24 residues) T helper epitope and binding site to the cellular receptor B3 142-161 (20 residueε) Hinge region and contactε between gp51 moleculeε in the trimer Table 2. Sequence of the oligonucleotides coding for the BLV epitopes for placing into BTV10 VP7 cDNA
Epitope Sequence
B1 5'-CTAGAAAATGAGCCAAGCCGATCAAGGGTCCTTTTATGTC
AATCATCAAATTTTATTCCTGCATCTCAAG-3' 5'-CTTGAGATGCTGGAATAAAATTTGATGATTGACATAAAA
GGACCCTTGATCGGCTTGGCTCATTTT-3' B2 5'-CTAGAAAATGAGTTTAAATCAAACGGCACGGGCCTTCCC
AGACTGTGCTATATGTTGGGAACCTTCCCCTCCCTGGGC
TCCCGAA-3* 5'-TTCGGGAGCCCAGGGAGGGGAGGGTTCCCAACATATAGCAC
AGTCTGGGAAGGCCCGTGCCGTTTGATTTAAACTCA
TTTT-3' B3 5'-CTAGAAAATGAGTAAAATTCCTGATCCCCCTCAACCCGAC
TTCCCTCAGCTGAACAGTGACTGGGTTCCCTCT-3' 5'-AGAGGGAACCCAGTCACTGTTCAGCTGAGGGAAGTCGGG
TTGAGGGGGATCAGGAATTTTACTCATTTT-3'
To generate the recombinant baculoviruεes, monolayerε of S_. frugiperda cellε were cotransfected with each of the three transfer vectors described above along with AcRP23-Lac Z DNA using lipofectin. Progeny viruseε with Lac Z-negative phenotype were plaque purified and selected by SDS-PAGE analyεiε and indirect immunoperoxidase (IIP) test using anti BTV10 rabbit serum and anti BTV10 VP7 monoclonal antibody (anti-VP7 MAb). Stock recombinant viruseε were checked by IIP teεt and Weεtern blot analyεiε uεing the anti BTV 10 VP7 (anti-VP7) and anti BLV gp51 εynthetic peptide (anti-pp) rabbit εera. IIP test.
The IIP test used was similar to that described by Sugiyama et al, (1989) Res. Vet. Sci. 46: 283-285. Briefly, Sf cellε infected with the recombinant baculoviruε in microtitreplateε were fixed with methanol, covered with blocking εolution (5% Skim milk in phoεphate-buffered saline), then probed with antibody followed by peroxidase-protein A (Bio Rad) . Bound peroxidaεe-protein A waε viεualized using o-phenylenediamine.
Infected Sf cellε and CLPs were analyzed by SDS-PAGE after SDS-mercaptoethanol treatment. Proteins were Western blotted to Immunobilon membrane (Millipore Corp. ) which were then soaked overnight in blocking solution, prior to probing with anti-VP7 or anti-pp sera followed by peroxidase-protein A, and detection using ECL syεtem (Amersham) .
The orientation of the chimeric gene in the tranεfer vectors were confirmed by εequence analyεiε (Fig. 10). Construction of the recombinant baculoviruses expresεing BLV B1-BTV10 VP7 chimera (AcBl-7) and BLV B3-BTV VP7 chimera and VP3 (AcVP3.B3-7) have been completed. The plaque purification of another recombinant viruε, AcVP3.B2-7, iε in progress. As shown in Table 3, all three recombinant virus proteins reacted with anti BTV10 rabbit serum and anti-VP7 MAb. Table 3. Immunoreactivi ies of antibodies with the recombinant baculovirus-infected Sf cells in
IIP test
Recombinant baculoviruses
Figure imgf000029_0001
*NT; Not tested
AcVP3. B3-7-infected Sf cells also reacted with anti-pp ( amino acid residue 142-161 ) rabbit serum, but AcBl-7 proteins did not react with anti-pp(98-117 ) rabbit serum. However, since the anti-pp(98-117 ) serum alεo did not react with BLV gp51 antigen (Table 4) , the expression of BLV Bl using anti BLV gp51 or anti BLV rabbit sera is being checked . Table 4. Immunoreactivities of antibodies with recombinant baculovirus- infected Sf cell lysate and BLV gp51 antigen in western blot
Recombinant baculovirus antibody AcVP3-7 AcBl-7 AcVP3. B3-7 BLV gp51
Anti-VP7 serum + NT Anti-pp(98-117) Anti-pp(142-161) -
Table 5. Formation of chimeric CPS. Recombinant baculovirus CLP -format ion
Chimeric AcBl-7 + AcBTV17.3 No
Chimeric AcBl-7 + AcBTVlO . 7-17.3 Yes
Chimeric AcVP3. B3-7 No Chimeric AcVP3. B3-7 + AcBTV10. 7 Yes Chimeric AcVP3. B3-7 + AcBTVlO . 7-17.3 Yes
Estimation of molecular weights using weεtern blot analyεiε showed that the chimeric proteins B1-VP7 and B3-VP7 , and BTV VP7 were 40kd, 42kd and 38kd as expected ( Fig . 11A) . Formation of chimeric CLP . s
CLPs were not formed in Sf cells coinfected with AcBl-7 and AcBTV17.3 or infected with AcVP3. B3-7 even though there was high levels of εynthesiε of both proteinε ( Table 5 ) . Chimeric CLPs formed only when • cells were coinfected with these recombinant viruses and a recombinant baculovirus expressing authentic VP7 . The presence of the chimeric protein ( B3-7 ) in the CLPs from the Sf cellε infected with AcVP3-7 waε confirmed by weεtern blot analyεi s using the anti-VP7 and anti-pp ( 142- 161 ) rabbit sera ( Fig. 12 ) .
EXAMPLE 4
Expreεεion of Hepatitiε B preS? epitopeε uεing modificationε and variationε of the VP7 gene waε carried out as followε.
E frugiperda cellε (ILPB-Sf21) and recombinant baculoviruses were propagated as described previously (25, 28). Standard procedures were used for plasmid DNA manipulations (27). Polymerase chain reaction (PCR) with subsequent proteinase K digeεtion waε performed aε deεcribed (30). For conεtruction of recombinant baculoviruses the transfer plaεmid vectorε containing foreign geneε were lipofected with Bεu36I cut Bac PAk6 DNA, white plaqueε were εelected and purified by two sequential plaque aεεayε (31). Purification of chimeric CLPε, SDS-polyacrylamide gel electrophoresiε, Weεtern blot and electron microεcopy were done aε deεcribed before (28). Amino terminal deletionε
VP7 vector uεed in our previouε εtudieε utilizeε amino terminuε of VP7 for attachment of foreign epitopes, though epitopes as large as 50 aa can be expressed on the surface of chimeric CLPs, the vector syεtem uεually needε co-infection with εome unmodified VP7. Otherwise in most cases particles are not formed or are unstable.
Therefore, amino terminal deletions of VP7 were constructed in order to extent the capacity of VP7 as a vector. If amino terminal sequenceε of VP7 are not neceεεary for the formation of CLPs, then they can be substituted for other amino acid sequenceε (foreign epitopeε) and the larger εequences (more than 50 aa) can be inserted.
Two amino terminal deletions of VP7 were constructed by the PCR technique using reverse primer: GGCGAGATCTTA.AGA.GAC.GTT.TAATG.GG
Bglll Direct primers: M E I L G I MEI GGCAGATCTACCATG.GAA.ATT.TTG.GGG.ATA.G (29 aa Bglll deletion) M A Q R N E M MAQ GGCAGATCTACCATG.GCA.CAA.AGA.AAT.GAG.ATG.T 55 aa Bglll deletion)
PCR fragments obtained with these primerε were treated with proteinaεe K, phenol and ethanol precipitated. After digeεtion with Bglll restriction endonuclease PCR fragmentε were cloned into BamHIεite of pAcYMl baculovirus expreεεion vector (32). Recombinant viruεeε were obtained uεing BacPAK6 linearized baculovirus DNA (31). Expreεsion of amino terminus truncated VP7 proteinε was verified on the Coomasεie blue stained polyacrylamide gelε. Aε expected, truncated VP7 proteins had molecular weights 24 kD(29 aε deletion) and 30 kD (55 aε deletion) .
For production of CLPε, S. frugiperda cellε were co-infected with recombinant baculoviruε expreεεing VP3 and recombinant baculoviruεeε expreεεing either VP7 (29 aa deletion), VP7 (55 aa deletion) or VP7 as a positive control. Cellε were lyεed 48 hr poεt-infected and CLPε were purified aε deεcribed previously (28). CLPs were produced only in control experiments with the undeleted VP7, but not with its truncated variants from which we concluded that amino terminal portion of VP7 is essential for formation of CLPs, and therefore replacement with foreign εequences is not posεible. Insertions to the hydrophilic regionε of VP7
The aim was to determine the regions within the VP7 molecule, that are able to carry extra sequences, since such regions could be advantageous for expression of conformational epitopes. Development of εuch vectorε are eεεential as that the majority of immunogenic epitopes is conformational.
Hydrophilic regions of VP7 have been targeted as, in general, hydrophobic regions are needed for intra-inter molecular interactions.
Two BstXI siteε (poεition 105 and 937 bp) were uεed to inεert amino acid sequences into VP7. Both siteε are εituated in parts of the VP7 gene coding for hydrophilic regionε of VP7. For the firεt εite (poεition 105), the VP7 tertiary structure iε known. Amino acid insertionε into it εhould be εituated in the loop between A and B β-sheets, therefore X-ray crystalographic studies are required. Therefore it can be expected that insertions into this site should not disturb the tertiary structure of VP7.
In order to test the poεεibility of uεing these εiteε for expreεεion of foreign epitopeε, oligonucleotide duplexeε coding for four amino acidε each were εyntheεized (Figure 13). pUC4K-BTV-10 S7 plaεmid containing S7 gene cloned in the BamHI εite of pUC4K vector was digested with BεtXI reεtriction endonuclease and p6/p7 and p8/p9 oligonucleotide duplexeε were ligated into it εeparately.
The resulting clones were checked by digeεtion with the BamHI and BεXI reεtriction endonucleaεeε (Figureε 14 and 15). VP7 geneε with insertions were excised out from the pUc4K vector and recloned into the BamHI cut and dephoεphorylated pAcYMI vector (32), and verified uεing BεXI digeεtion.
Recombinant baculoviruεeε expresεing VP7 variantε with inεertionε were produced aε deεcribed above. S. frugiperda cellε were coinfected with recombinant baculoviruεeε expreεsing VP3 and VP7 with insertions. CLPs were produced with unmodified VP7, but not with VP7 variants carrying 4 aa insertionε.
Therefore, it waε concluded that εiteε which were uεed for inεertionε are not εuitable for vector purposes.
Internal Point Mutations
Two different point mutations of VP7 gene were prepared with the εimultaneouε introduction of unique cloning εiteε in order to uεe them for cloning of foreign immunogenic epitopeε. BTV10 VP7 gene waε cloned in BamHI εite of the pAcCL29 plaεmid baculovirus expreεsion vector with single-stranded capacity (8). The utationε are shown on Figure 16. Restriction endonuclease analysis of mutated genes is shown on Figure 17.
One mutation iε a change of Lyε255 to Ser creating a Seal site, and another iε a change of Glyl69 to Ser which creates the Bglll cloning εite. The second mutation is of particular interest, because it mutateε RGD motif of VP7 which iε often involved in cell receptor binding. Therefore, it is probably that RGD motif is on the εurface of CLPε, and may be uεed for preεentation of foreign epitopeε.
Recombinant baculoviruεeε expreεsing mutated VP7 genes have been conεtructed. In experimentε where S. frugiperda insect cells were co-infected with recombinant baculoviruses expressing VP3 and mutated VP7s (separately), it has been established that both mutations permit the formation of CLPs. However, in the case of Lys to Ser mutation, CLPs appeared to be incomplete and lacking some VP7. In case of Gly to Ser mutation, perfect CLPs were formed, which had no visible difference from CLPε produced with unmutated VP7. Thiε site will be developed for cloning foreign immunogenic epitopes.
EXAMPLE 5
Expresεion of Helicobacter pylori urease subunits A and B epitiopeε as CLPs was investigated aε followε. Helicobacter pylori iε a causative agent of peptic ulcer. Production of Helicobacter pylori urease is of interest for the development of a vaccine against this diseaεe (33).
Dual baculoviruε expreεεion vector pAcUW3 waε used for the expresεion of both A and B subunitε of Helicobacter pylori uεing εingle baculoviruε (34). Polymeraεe chain reaction (PCR) waε performed aε deεcribed (30). For conεtruction of the recombinant baculoviruε, the plaεmid tranεfer vector containing urease A and B εubunitε waε lipofected with Bεu36.1 cut BacPAK6. DNA, white plaqueε were selected and purified by two εequential plaque aεεayε (31). Polyacrylamide gel electrophoreεiε were done as described before (28).
Genes coding for the Helicobacter pylori urease subunits A and B were produced by PCR, using 2.7 kb Taql clone (W. Thomas) aε a template. PCR fragmentε containing structural genes coding for the urease subunitε were cloned in the pAcUW3 vector, ureaεe A εubunitε in the BgHI εite, under the control of the polyhedrin promoter. Orientation of PCR fragmentε in the pAcUW3 A, B. plasmid was established using Hindlll restriction endonuclease.
Recombinant baculoviruses were produced using this plasmid. When S. frugiperda cellε were infected with this recombinant baculovirus, both urease A and B subunits were produced (Figure 18). Both A and BV subunits react with anti-urease antibodies on the Western blot (Figure 19). Expresεion of the εubunit A waε very good, whereaε the εubunit B waε not expreεεed to εuch a high level. Subunit B appearε to be highly unεtable, a ladder of ureaεe-εpecific bandε could be εeen on the Weεtern blot. Thiε might be one of the reasons for its modeεt expression.
EXAMPLE 6
It has been demonstrated previously that the three minor proteins of BTV, VPl, VP4 and VP6 can be incorporated into CLPs when expressed by baculovirus vectors. The preεent example deεcribes efforts to determine whether these proteins could be developed for the delivery of foreign epitopes within the CLPε. To this end, the present example describes efforts to exploit VP6 proteins by deletion mutationε and εubsequently inεertion of the foreign epitope. The deletion of carboxy termini of VP6 haε been demonstrated to be encapsidated within CLPε.
A chimeric protein with a T-helper epitope from the gag gene of SIV (41 to 62) amino acid) on the carboxy terminuε (Hindlll site by removing 23 amino acids) of VP6 protein of BTV was constructed. The resulting protein was encapsidated in the core-like particles (CLPε).
The SIVgag epitope was εyntheεiεed by PCR uεing the εtandard protocol. The cloned SIVgag gene waε used as the template and the following nucleotides as primers: 1. Forward primer
Hindlll 5' C G C G A A G C T T C G C A A G C A C T G T C A G A A G G
2. Reverεe primer
HindiII BamHI 51 G C G C A A G C T T G G A T C C T A T T G A T G G T C T C C
A Hindlll εite on the forward and Hindlll and BamHI εiteε on the reverse primerε were kept.
Conεtruction of Chimeric Plaεmid
The plaεmid pUC19 containing VP6 cDNA waε digeεted with Hindlll and the large fragment gel purified. The PCR εyntheεiεed Hindlll digeεted fragment waε cloned into the gel purified large fragment and the orientation and εequence was checked by sequencing. Construction of Transfer Vector
The chimeric VP6 SIV gene was excised from pUC19 by digestion with BamHI and cloned at the BamHI εite by the baculoviruε tranεfer vector pAcYMI. The orientation waε checked by εequencing. Preparation of recombinant baculovirus expressing SIV epitope with BTV VP6
A monolayer of Sf21 cells was co-transfer vector and Bεu361 digeεted baculovirus bakPac6 DNA. The supernatant containing the progeny viruses was collected at 60 hr. p.i. and the recombinant viruseε were plaque purified (white plaques) against wild types (blue plaques) . Encapεidation of SIV VP6 in CLPε
The cells were co-infected with a dual recombinant baculovirus expreεsing VP3 and VP7, and SIV VP6 recombinant baculovirus. The CLPs were purified at 48 hr p.i.
Construction of. recombinant baculoviruε
.expressing SIV VP6 chimeric protein
The construction of this recombinant is complete. The expresεion of the chimeric protein was analyzed by in vitro labelling with 35S methionine and SDS-PAGE (compared with the native VP6 protein). Both have the same molecular weight aε 23 amino acidε are deleted from the native VP6 and 23 have been added to the chimeric protein (gag epitope). Encapεidation of SIV VP6 in CLPε
On co-infection with dual recombinant viruε, SIV VP6 waε encapsidated within the CLPs formed by VP3 and VP7.
Currently, large quantities of CLPs containing SIV-VP6 have been prepared and inoculated into mice. Evaluation of the immunogenicity of the chimeric SIV, mainly be T cell responses is underway. The future plan iε to exploit VP6 proteinε for preεentation of T cell epitopes of foreign immunogens.
The vaccineε of the invention in are formulated by methodε known in the art, εuch aε for example by εimple mixing. The vaccineε are employed in amounts readily determined by one of ordinary εkill. For adults, a εuitable doεage iε in the range of 10 μg to 100 mg, for example 50 μg to 50 mg. Similar dosages will be applicable for children. Carrier syεtems for humans may include enteric releaεe capεuleε protecting the antigen from the acidic environment of the stomach.
Adjuvants may alεo be employed. A εuitable mucosal adjuvant is cholera toxin. Others which may uεed are non-toxic derivativeε of cholera toxin. The amount of adjuvant employed dependε on the type uεed. Typically, when cholera toxin iε employed, it is used in an amount of about 5 μg to 50 μg, e.g. 10 μg to 35 μg. Suitable carriers are enteric capsuleε and polylactide-glycolide microεphereε. Suitable diluentε are 0.2N NaHCO, and/or εaline.
Preferred modeε of administration are orally, nasally, rectally or ocularly. Oral administration can provide delivery to other G.I. mucoεa including intestinal mucosa. The vaccine may be administered to mucosal surfaceε aε an aeroεol, εuεpenεion, capεule, and/or εuppoεitory. The method of administration will be readily apparent to a perεon of ordinary εkill in this art.
In εummary, BTV structural protein chimeras have been constructed based on VP7 containing well-studied immunogenic regionε of variouε foreign viral antigenε (e.g., rabieε viruε glycoprotein G, hepatitiε B viruε preS? region, HIV and SIV gag and env proteinε). A 10 amino acid reεidue εequence repreεenting an immunogenic region of rabieε G protein waε introduced to the amino terminus of VP7 and the chimeric protein was expresεed by a recombinant baculoviruε and incorporated into CLPε and VLPε on co-expreεεion with other BTV proteinε. The particleε ha been used to elicit immune reεponεe in mice and εhown to produce sera that recognize, by Weεtern blot analyεis, authentic rabies G protein. Similarly a chimeric VP7 protein containing most of the hepatitiε B viruε preS? region (amino acid residues 1-48) upstream to, and co-linear with the amino-terminus of VP7 protein (preS2-VP7) waε expressed and incorporated into the CLPs in the presence of authentic VP7 and VP3. Both VP7 proteins were incorporated into CLPε. The ratio of preS?-VP7 incorporated into CLPε waε influenced by the expreεεion level of authentic VP7. Immunoelectron microεcopy of the chimeric particles indicated that the preS2 epitope was exposed on the surface of the CLPε.
For HIV and SIV gag and env protein three different regionε for inεertion into chimeric VP7 (e.g., the VP3 loop of HIV-1 env, the amino acid reεidues 41-60 of SIV gag, and the amino acid residues 161-180 of SIV gag protein) have been tested. Each of these epitopeε were fuεed with the amino-terminuε of BTV VP7 protein and expreεεed by recombinant baculoviruses. Each recombinant virus was then used to infect insect cells together with a εecond recombinant viruε expressing the BTV VP3 protein in order to form CLPs. Both biochemical and electron microscopic analyses indicated that the chimeric CLPs were formed that were similar to the BTV CLPs. Immunogold-negative stain electron microscopic analyseε revealed that theεe epitopeε were expoεed on the εurface of CLPε. Chimeric VLPε were alεo conεtructed in which the V3 loop of the HIV env protein was inserted into the N-terminuε of BTV VP7 and co-expreεεed with recombinant baculoviruεeε expressing VP3 as well as (1) BTV VP2 and (2) BTV VP5.
The data obtained indicates that when a large epitope, e.g. the 48 amino acids of HBV preS2 was incorporated into the amino terminuε of BTV VP7, it blocked the formation of CLPε on co-expreεεion with BTV VP3. However when co-expreεεed with a dual gene vector that made VP7 and VP3 the chimeric protein waε incorporated.
By contrast when a εmall epitope, e.g. the 10 amino acid εequence repreεenting a rabieε G sequence, waε incorporated into the VP7 amino terminuε, CLPε were formed on co-expreεεion with VP3 alone. Similarly, it haε been found that uεing chimeric VP7 including an N-terminal εequence derived from the hypervariable region of the HIV V3 loop (30 amino acid residues) CLPs can be formed in the absence of authentic VP7 protein.
The VP7 of BTV exists on the εurface of CLPs as trimers. Recent analyses have shown that when insufficient VP7 is made in co-infections with vectors that synthesize large quantities of VP3, incomplete CLPs are produced, CLPs that lack some of the surface arrangement of VP7. It is poεεible that VP7 is added sequentially to the VP3 subcore, firεt to poεitionε that stabilize the structure and εecond to poεitionε that complete the CLP εurface εtructure. By thiε model, when a chimeric VP7 iε unable to produce a CLP with VP3 alone, εupplementation with unmodified VP7 protein allowε incorporation of the chimeric protein.
The present invention is concerned with the expression of chimeric VP7 proteins containing 48 amino acid residues of the hepatitis B viruε (HBV) pre-S2 region, 30 amino acid residueε of the HIV-1 V3 loop, and 10 amino acids of rabieε viruε G-protein. The chimeric VP7 proteinε were expreεεed in baculoviruε together with native BTV structural proteins to produce chimeric CLPs and VLPε.
In the case of the largeεt chimeric protein, VP7/HBV pre-S_, the protein, although not included into CLPs when expreεsed with VP3, was included into CLPs when co-expressed with VP3 and VP7, indicating that the particles can accommodate various forms of VP7. The biological and immunological characteriεticε of theεe particleε have been analyzed. The HBV epitopeε were localized to the surface of the CLPs as demonstrated using immunogold electron microscopy.
The chimeric protein formed BTV corelike particles (CLPs) in S. frugiperda cells only when the cells were co-infected with thiε recombinant viruε and a recombinant baculoviruε that expreεses unmodified VP7 and VP3 of BTV. The ratio of preS2-VP7 incorporated into CLPε waε influenced by the relative multiplicities of infection of the two viruεeε. Immuno-electron microεcopy of the chimeric particles indicated that the preS2 epitope was exposed on the surface of the CLPs. When insect cells were co-infected with the preS2~VP7 recombinant virus and a baculovirus vector that εyntheεized only the VP3 protein, no CLPε were identified.
The εyntheεis of high levelε of BTV chimeric CLPs offers a novel approach for presenting large epitopes. The immunogenity of foreign epitopeε presented by εuch CLPs was demonstrated in mice.
In addition to the epitopes presented as part of the chimeric protein of the VLPs or CLPε of the invention, the εtructure of typical VLPε and CLPε can allow additional antigenε to be incorporated, for example in a hollow central region. Thuε multivalent vaccines can be produced utilizing the procedures described herein.
CLPs and VLPs produced according to the invention offer several particular advantages over other systemε. Firεt, large quantitieε can be produced, eεpecially when use iε made of the expreεsion capabilities of baculovirus vectors (e.g. the potential for production at 20-30 mg per liter culture, the potential for production in serum-free medium, and stability to freeze-drying) . Second, CLPs and VLPs can be purified using a one-step generic protocol based on the physical propertieε of the particle (gradient centrifugation of cell lyεateε). Third, they can be produced in a form which iε εubεtantially devoid of any detectable amountε of foreign e.g. inεect, or baculoviruε proteins and of RNAs or DNAε. Fourth, purification procedureε can be used which are gentle enough to maintain the morphological structure of the particles in their native conformationε. Fifth, the particleε can be made in a form which do not replicate although they can efficiently attach to and be taken up by cellε. Sixth, CLPs and VLPs, especially those based on BTV, can tolerate a wide range of additional protein εequenceε without disruption, allowing multiple epitopes to be accommodated. Lastly, and moεt important, VLPε can be produced which have inherent propertieε of inducing both B cell and T cell reεponεeε in vertebrate hoεtε.
In εummary, CLPs and VLPs have been developed which can deliver multiple peptide componentε repreεenting viral epitopes in order to elicit protective immunity. The CLPε and VLPε, especially those of BTV, are large multiprotein structures.
They can incorporate alternative protein forms of the structural proteins (e.g., chimeric VP7), including alternative forms of these proteinε (e.g. VP7a and VP7b) . In addition, there is a poεεibility to use more than one of the protein types to deliver antigens (e.g., VP2 and/or VP5 and/or VP7). Thiε feature haε important implicationε, e.g. to decreaεe the chance of non-reεponεiveneεε: vaccines designed to elicit immunity should preferably not be based on a single viral sequence or antigen but εhould include aε many immunogenic sequences as feasible. VLPε baεed on alternative BTV εerotypes can alεo be employed for εucceεεive immunizationε in order to evade anti-BTV reεponses elicited in a primary vaccination. Thiε iε an eεpecially uεeful feature of the BTV εyεtem, not currently available in other antigen delivery systems (e.g., vaccinia, polio, Ty particles or Salmonella vectors) .
The high levels production of CLPs and VLPs from baculovirus vectors suggest that this syεtem may be adopted aε a carrier εyεtem in which multiple foreign antigens can be presented to the immune systems to induce both cellular and humoral immunity.
In accordance with the invention, foreign antigens can be expresεed aε epitopeε on protein componentε of CLPε and VLPε in a manner which enableε the epitopeε to be located in an internal εite in the CLPs and VLPs. Thiε can protect the foreign antigenε from proteolysiε and/or antibody attack until it reaches a desired location. This may for example be achieved with a chimeric VLP in which the VP7 iε in chimeric form. Similarly, having regard to the known interaction of VP3 with minor BTV proteinε, formation of chimeric analogueε of such minor proteins allows further opportunities of introducing foreign geneε at εiteε which can lie in protected locationε in the reεulting chimeric VLPs.
REFERENCES
1 Valenzuela, P., Coit, D. , Medina-Selby, A.,
Kuo, C.H., Van Nest, G. , Burke, R.L., Bill, P., Urdea, M.S. and Graves, P.V. (1985). Bio/Technology 3:323-326.
2. Michel, M.L., Mancini, M. , Riviere, Y. , Dormont, D. and Tiollais, P. (1990). Journal of Virology 64:2452-2455.
3. Clarke, B.E., Newton, S.E., Carroll, A.R., Francis, M.J., Appleyard, G. , Syred, A.D., Highfield, P.E., Rowlands, D.J. and Brown, F. (1987). Nature 330:381-384.
4. Evanε, D.J., McKeating, J., Meredith, J.M., Burke, K.L., Katrak, K. , John, A., Ferguson, M., Minor, P.D., Weiεs, R.A., Almond, J.V. (1989). Nature 339:385-388.
5. Griffiths, J.C., Berrie, E.L., Holdworth, L.N., Moore, J.P., Harriε, S.J., Senior, J.M., Kingεman, A.J., and Adamε, S.E. (1991). J. Virol. 65:450-456.
6. French, T.J., Marεhall, J.J.A. and Roy, P. (1990). J. Virol. 64:5695-5700.
7. Loudon, P. and Roy, P. (1991). Virology 180:798-802.
8. Ganem, D. and Varmuε, H.E. (1987). H.E. Ann. Rev. Biochem. 56:651-633.
9. Galibert, F., Mandart, E., Fitouεεi, R. , Tiollais, P. and Charnay, P. (1979). NAture 281:646-650.
10. Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982). "Molecular Cloning: A Laboratory Manual". Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
11. Matεuura, Y. , Possee, R.D., Overton, H.A. and Bishop, D.H.L. (1987). J. Gen. Virol. 68:1233-1250.
12. Sanger, D.V., Nicklen, F.S. and Coulson, A.R. (1977). Proc. Natl. Acad. Sci. 74:5963-5467.
13. Kittε, P.A., Ayerε, M.D. and Poεεee, R.D. (1990). Nucl. Acidε Reε. 18/19 pp. 5667.
14. Feigner, P.L., Gadek, T.R., Holm, M. , Roman, R., Chan, H.W. , Wenz, M. , Northrop, J.P., Ringold, G.M. and Danielεen, M. (1987). Proceedingε of Natl. Acad. of Sci. USA 84:7413-7417.
15. Oldfield, S., Adachi, A., Urakawa, T. Hirasawa, T. and Roy, P. (1990). J. Gen. Virol. 71:2649-2656.
16. Inamura, S., Ghiasi, H. and Roy, P. (1987). J. Gen Virol. 68:1627-1635.
17. French, T.J., Marshall, J.J.A. and Roy, P. (1990). J. Gen. Virol. 64:5695-5700.
18. Smith, D.B., Johnson, K.S. (1988). Gene 67:31-40.
19. Prasad, B.V.V., Yamaguichi, S. and Roy, P. (1992). J. Virol, (in press).
20. Hewat, E.A., Booth, T.F., Wade, R.H. and Roy, P. (1991). J. Struct. Biol. (submitted).
21. Dehoux, P., Ribeε, V., Sobczak, E. and Streeck, R.E. (1986). Gene 8:155-163.
22. Kniεkern, P.J., Hagopian, A., Burke, P., Dunn, N. , Emini, E.A., Miller, W.J., Yanasaki, S. and Ellis, R.W. (1988). Hepatology 8:82-87.
23. Itoh, Y. , Hayakawa, Y. and Fujiεawa, Y. (1986). Biocehm. Biophys. Reε. Commun. 138:268-274. 24. Jacobε, E., Rutgers, T., Voet, P., Dewerchin, M., Cabezon, T. and De Wilde, M. (1989). Gene 80:279-291.
25. Poεεee, R.D. (1986). Viruε Reεearch. 5:43-59
26. Poεεee, R.D. and Howard, S.C. (1987). Nucleic Acidε Reεearch 15:10233-10248.
27. Maniatis, T. , Fritsch, E.F. and Sambrook, J. (1982). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Presε, Cold Spring Harbor, N.Y.
28. Belyaev, A.S. et al, (1992) Virology 190: 840-844.
29. French, T.J. and Roy, P. (1990) J. Virol. 64: 1530-1536.
30. Crowe, J.S. et al (1991) Nucleic Acidε Reεearch 19:184.
31. Kittε P.A. and Poεsee R.D. (1993) Biotechniqueε (in preεε) .
32. Matεuura et al (1987) J. General Virology 68: 1627-1635.
33. Mobley, H.I.T. and Hauεinger, R.P. (1989) Microbiol. Rev. 53: 85-108
34. Wayler U. and Poεεee R. D. (1991) J. Gen. Virol.72: 2967-2974.

Claims

1. An antigen in particulate form comprising a plurality of proteins capable of aεεembly in cooperation with one another into viruε-like particleε (VLPε) or viruε core-like particles (CLPs), characterized in that the particleε include two or more different proteinε each of which compriεeε amino acid εequenceε derived from native proteinε of a εelected viruε species and at least one of the proteins is chimeric and comprises an amino acid εequence derived from a foreign protein other than εaid native protein.
2. An antigen in particulate form as claimed in claim 1 conεiεting of a CLP compriεing two essential proteinε and one or more further optional proteins, wherein said eεsential proteins are selected from virus major inner capεid proteinε and the optional proteinε are selected from minor inner capsid proteinε.
3. An antigen in particulate form as claimed in claim 2 comprising zero, one, two or three further optional viruε minor inner capεid proteinε.
4. An antigen in particulate form as claimed in claim 1 conεiεting of a VLP comprising three esεential and one or more further optional proteinε, wherein two of εaid esεential proteinε are viruε major inner capεid proteinε, one of said eεsential proteins is a virus major outer capsid protein and the optional proteins are selected from minor inner capεid proteinε and major outer capεid proteinε.
5. An antigen in particulate form aε claimed in claim 4 compriεing zero or one further optional viruε major outer capsid proteins.
6. An antigen in particulate form as claimed in claim 4 or claim 5 comprising zero, one, two or three further optional virus minor inner capsid proteins.
7. An antigen in particulate form as claimed in any preceding claims wherein the amino acid sequence derived from the foreign protein includes an epitope which iε recognized by an antibody to said foreign protein.
8. An antigen in particulate form aε claimed in any preceding claim wherein the foreign protein iε a protein of a diεease organism and said antigen in particulate form is capable of raising protective antibodies or cellular immune reεponεeε in organism suεceptible to the diεeaεe.
9. An antigen in particulate form aε claimed in any preceding claim including at least one of said different proteinε in native form.
10. An antigen in particulate form as claimed in any preceding claim wherein only one of said different proteins is chimeric.
11. An antigen in particulate form as claimed in any preceding claim wherein said different proteins include both of εaid firεt and second proteins in native form, and in addition, one of εaid firεt and εecond proteinε in chimeric form.
12. An antigen in particulate form aε claimed in any preceding claim wherein εaid firεt and εecond proteinε compriεe amino acid εequenceε derived from proteinε of a viruε of the family Reoviridae.
13. An antigen in particulate form as claimed in claim 12 wherein said first and second proteinε compriεe amino acid εequenceε derived from proteinε of an orbiviruε, a rotaviruε or a reoviruε.
14. An antigen in particulate form aε claimed in claimε 12 to 13 wherein εaid proteins compriεe amino acid εequenceε derived from bluetongue viruε proteinε.
15. An antigen in particulate form aε claimed in any preceding claim conεisting of a CLP compriεing two eεsential proteins and one or more further optional proteinε, wherein εaid eεεential proteinε are viruε major inner capsid proteins VP3 and VP7 and the optional proteinε are εelected from the minor capsid proteins VPl, VP4 and VP6.
16. An antigen in particulate form as claimed in claim 15 consiεting of the one of the following combinations of proteins:
VP3 + VP7
VP3 + VP7 + VPl
VP3 + VP7 + VP4
VP3 + VP7 + VP6
VP3 + VP7 + VPl + VP4
VP3 + VP7 + VP4 + VP6
VP3 + VP7 + VPl + VP6
VP3 + VP7 + VP6 + VP4 + VP6
17. An antigen in particulate form as claimed in any preceding claim consiεting of a VLP compriεing three essential proteins and one or more further optional proteins, wherein two of said essential proteins are virus major inner capsid proteins VP3 and VP7y one of said eεεential proteins is a viruε major outer capsid protein selected from VP2 and VP5 and the optional proteins are selected from minor inner capsid proteins VPl, VP4 and VP6 and major outer capsid proteins VP2 and VP5.
18 An antigen in particulate form aε claimed in claim 17 consisting of the one of the following combinations of proteins:
VP2 + VP3 + VP7
VP2 + VP3 + VP7 + VPl
VP2 + VP3 + VP7 + VP4
VP2 + VP3 + VP7 + VP6
VP2 + VP3 + VP7 + VPl + VP4
VP2 + VP3 + VP7 + VPl + VP6
VP2 + VP3 + VP7 + VP4 + VP6
VP2 + VP3 + VP7 + VP6 + VP4 + VP6
VP5 + VP3 + VP7
VP5 + VP3 + VP7 + VPl
VP5 + VP3 + VP7 + VP4
VP5 + VP3 + VP7 + VP6
VP5 + VP3 + VP7 + VPl + VP4
VP5 + VP3 + VP7 + VPl + VP6
VP5 + VP3 + VP7 + VP4 + VP6
VP5 + VP3 + VP7 + VP6 + VP4 + VP6
VP2 + VP5 + VP3 + VP7
VP2 + VP5 + VP3 + VP7 + VPl
VP2 + VP5 + VP3 + VP7 + VP4
VP2 + VP5 + VP3 + VP7 + VP6
VP2 + VP5 + VP3 + VP7 + VPl + VP4
VP2 + VP5 + VP3 + VP7 + VP4 + VP6
VP2 + VP5 + VP3 + VP7 + VPl + VP6
VP2 + VP5 + VP3 + VP7 + VP6 + VP4 + VP6
19. An antigen in particulate form as claimed in any of claimε 16 to 19 wherein εaid proteins are bluetongue viruε proteinε BTV-VP3 and BTV-VP7.
20. An antigen in particulate form aε claimed in claim 10 wherein the εaid proteinε include chimeric BTV-VP7 compriεing amino acid sequences derived from native BTV-VP7 and an amino acid sequence derived from a foreign protein other than BTV-VP7.
21. An antigen in particulate form as claimed in claim 20 wherein the VLPs or CLPε include (i) native BTV-VP3, (ii) native BTV-VP7 and (iii) chimeric BTV-VP7 and an amino acid sequence derived from a foreign protein other than BTV-VP7.
22. An antigen in particulate form aε claimed in any preceding claim wherein said foreign protein is a human immunodeficiency virus (HIV) protein or a protein of human hepatitiε viruε (e.g. HBV).
23. A method of producing a VLP or CLP comprising at least one non-native protein compriεing aεεembling εaid VLPε or CLPε from a plurality of different proteinε including firεt and εecond native viruε proteinε and εaid non-native protein, characterized in that εaid non-native protein iε a chimeric and compriεeε an amino acid εequence derived from a foreign protein and an amino acid εequence derived from one of εaid first and εecond native virus proteins.
24. A method according to claim 23 wherein said first and εecond different proteinε compriεeε amino acid εequenceε derived from proteinε of an orbiviruε, a rotaviruε or a reoviruε.
25. A method according to claim 24 wherein said firεt and εecond different proteinε comprise amino acid sequenceε derived from bluetongue viruε proteinε.
26. A method according to claim 25 wherein εaid bluetongue viruε proteinε are BTV-VP3 and BTV-VP7.
27. A method according to claim 26 wherein the VLPε or CLPε include chimeric BTV-VP7 compriεing amino acid εequenceε derived from native BTV-VP7 and an amino acid sequence derived from a foreign protein other than BTV-VP7.
28. A method according to claim 26 wherein the VLPε or CLPs include (i) native BTV-VP3, (ii) native BTV-VP7 and (iii) chimeric BTV-VP7 compriεing amino acid sequenceε derived from native BTV-VP7 an amino acid εequence derived from a foreign protein other than BTV-VP7.
29. A method according to any of claimε 23 to 28 wherein εaid amino acid sequence derived from a foreign protein iε located at the N-terminal and of the chimeric protein.
30. A method according to any of claimε 23 to 29 wherein the conεtituent proteins are co-expressed.
31. A method according to any of claimε 23 to 30 wherein the expreεεion εyεtemε includeε a baculoviruε expreεεion vector.
32. A method according to any of claimε 24 to 31 wherein the conεtituent proteins are expresεed in inεectε or inεect cellε.
33. A vaccine compoεition comprising an effective amount of an antigen according to claim 1, in association with a therapeutically acceptable carrier or diluent.
34. A method of inducing a protective immunogenic responεe in a hoεt in need of treatment, εaid method compriεing the εtep of administering to the host an effective amount of an antigen according to claim 1.
35. A method according to claim 34, wherein said antigen iε adminiεtered to a mucoεal εurface of εaid hoεt.
36. A method according to claim 35, wherein εaid antigen iε adminiεtered orally.
PCT/US1993/006634 1992-07-16 1993-07-15 Multiple particulate antigen delivery system Ceased WO1994002173A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU47732/93A AU4773293A (en) 1992-07-16 1993-07-15 Multiple particulate antigen delivery system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929215101A GB9215101D0 (en) 1992-07-16 1992-07-16 Multiple particulate antigen delivery system
GB9215101.8 1992-07-16
US97115892A 1992-11-04 1992-11-04
US971,158 1992-11-04

Publications (1)

Publication Number Publication Date
WO1994002173A1 true WO1994002173A1 (en) 1994-02-03

Family

ID=26301262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/006634 Ceased WO1994002173A1 (en) 1992-07-16 1993-07-15 Multiple particulate antigen delivery system

Country Status (6)

Country Link
CN (1) CN1084218A (en)
AU (1) AU4773293A (en)
IL (1) IL106362A (en)
MX (1) MX9304310A (en)
PT (1) PT101310A (en)
WO (1) WO1994002173A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002836A1 (en) * 1995-07-07 1997-01-30 Oravax, Inc. Clostridium difficile toxins as mucosal adjuvants
EP0877623A4 (en) * 1995-07-07 1998-11-18
US5919463A (en) * 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
WO2001002551A3 (en) * 1999-06-30 2001-11-08 Evotec Biosystems Ag Virus like particles, preparation and use in screening and functional genomics
EP1219705A1 (en) * 2000-12-29 2002-07-03 Evotec OAI AG Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7419802B2 (en) 1999-06-30 2008-09-02 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
WO2017182958A1 (en) * 2016-04-19 2017-10-26 Csir Plant-produced chimaeric orbivirus vlps

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
GENE, Volume 67, issued July 1988, LANGLEY et al., "Characterization of Purified Hepatitis B Surface Antigen Containing Pre-S(2) Epitopes Expressed in Saccharomyces Cerevisiae", pages 229-245. *
JOURNAL OF GENERAL VIROLOGY, Volume 70, issued June 1989, URAKAWA et al., "Synthesis of Immunogenic, but Non-Infectious, Poliovirus Particles in Insect Cells by a Baculovirus Expression Vector", pages 1453-1463. *
JOURNAL OF VIROLOGY, Volume 64(12), issued December 1990, FRENCH et al., "Assembly of Double-Shelled, Viruslike Particles of Bluetongue Virus by the Simultaneous Expression of Four Structural Proteins", pages 5695-5700. *
JOURNAL OF VIROLOGY, Volume 64(3), issued March 1990, JENKINS et al., "An Antigen Chimera of Poliovirus Induces Antibodies Against Human Papillomavirus Type 16", pages 1201-1206. *
JOURNAL OF VIROLOGY, Volume 64(4), issued April 1990, FRENCH et al., "Synthesis of Bluetongue Virus (BTV) Corelike Particles by a Recombinant Baculovirus Expressing the Two Major Structural Core Proteins of BTV", pages 1530-1536. *
JOURNAL OF VIROLOGY, Volume 65(9), issued September 1991, LEBLOIS et al., "Synthesis and Characterization of Chimeric Particles between Epizootic Hemorrhagic Disease Virus and Bluetongue Virus: Functional Domains are Conserved on the Vp3 Protein", pages 4821-4831. *
NATURE, Volume 339, issued 01 June 1989, EVANS et al., "An Engineered Poliovirus Chimaera Elicits Broadly Reactive HIV-1 Neutralizing Antibodies", pages 385-388. *
VIROLOGY, Volume 180(2), issued February 1991, LOUDON et al., "Assembly of Five Bleutongue Virus Proteins Expressed by Recombinant Baculoviruses: Inclusion of the Largest Protein VP1 in the Core and Virus-Like Particles", pages 798-802. *
VIROLOGY, Volume 182(2), issued June 1991, LOUDON et al., "Expression of the Outer Capsid Protein VP5 of Two Bluetongue Viruses, and Synthesis of Chimeric Double-Shelled Virus-Like Particles Using Combinations of Recombinant Baculoviruses", pages 793-801. *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002836A1 (en) * 1995-07-07 1997-01-30 Oravax, Inc. Clostridium difficile toxins as mucosal adjuvants
EP0877623A4 (en) * 1995-07-07 1998-11-18
US5919463A (en) * 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
WO2001002551A3 (en) * 1999-06-30 2001-11-08 Evotec Biosystems Ag Virus like particles, preparation and use in screening and functional genomics
US7419802B2 (en) 1999-06-30 2008-09-02 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
EP1219705A1 (en) * 2000-12-29 2002-07-03 Evotec OAI AG Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
WO2017182958A1 (en) * 2016-04-19 2017-10-26 Csir Plant-produced chimaeric orbivirus vlps
US11053509B2 (en) 2016-04-19 2021-07-06 Csir Plant-produced chimaeric Orbivirus VLPs
US12215328B2 (en) 2016-04-19 2025-02-04 Csir Plant-produced chimaeric orbivirus VLPs

Also Published As

Publication number Publication date
IL106362A0 (en) 1993-11-15
CN1084218A (en) 1994-03-23
PT101310A (en) 1994-05-31
MX9304310A (en) 1995-01-31
AU4773293A (en) 1994-02-14
IL106362A (en) 1998-12-06

Similar Documents

Publication Publication Date Title
US5591823A (en) Expression of specific immunogens using viral antigens
EP0652967B1 (en) Self-assembling replication defective hybrid virus particles
EP0433371A1 (en) Fusion protein of paramyxovirus, method of production using recombinant baculovirus expression vector, vaccine comprising such protein and use thereof
US7645455B2 (en) Chimeric lyssavirus nucleic acids and polypeptides
EP0652957B1 (en) Assembled viral particles and their use in a vaccine to rotaviral disease
EP0577894B1 (en) Design, construction and expression of chimeric proteins for development of vaccines and diagnostic reagents
US5667782A (en) Multiple particulate antigen delivery system
WO1994002173A1 (en) Multiple particulate antigen delivery system
Belyaev et al. Presentation of hepatitis B virus preS2 epitope on bluetongue virus core-like particles
WO1984002847A1 (en) Methods and materials for development of parvovirus vaccine
CN115161344A (en) Preparation method of vaccine for respiratory syncytial virus infection
US5632992A (en) Process for the expression of herpes simplex virus type 1 glycoprotein E and method of use
US6521236B1 (en) Vector vaccine of recombinant feline herpesvirus
AU604791B2 (en) Viral vector and recombinant DNA coding, in particular, for the p25 protein of the virus that is a causal agent of aids, infected cell culture, protein obtained, vaccine and antibodies obtained
EP1171454B1 (en) Chimeric lyssavirus nucleic acids and polypeptides
AU664597B2 (en) Process for the expression of herpes simplex virus type 1 glycoprotein I and methods of use
JPS63500637A (en) recombinant virus
AU660528B2 (en) Process for the expression of herpes simplex virus type 1 glycoprotein E and methods of use
US7238672B1 (en) Chimeric lyssavirus nucleic acids and polypeptides
US5672349A (en) Process for the expression of herpes simplex virus type 1 glycoprotein I and methods of use
AU665195B2 (en) Immunogenic peptides or polypeptides of the BVD virus and related viruses, vaccines incorporating them or expressing them, methods and means of production thereof
EP1721982B1 (en) Chimeric lyssavirus nucleic acids and polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA